Treatment of acute medical conditions
Electrical stimulation of the splenic nerve addresses the inadequacies of current treatments for acute diseases by stabilizing blood pressure and improving vital signs in conditions like septic shock, enhancing survival rates.
Patent Information
- Application Number
- JP2024113787
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-12-20
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-19
AI Technical Summary
Current treatments for acute diseases such as trauma, hemorrhage, and septic shock are often unsuccessful and require immediate medical intervention to alleviate suffering and minimize morbidity and mortality.
Electrical stimulation of the splenic nerve, particularly the splenic artery nerve, to modulate neural activity and improve physiological parameters including blood pressure, heart rate, and oxygen saturation.
Stabilizes blood pressure, improves cardiovascular function, and enhances survival in endotoxemic shock models by increasing oxygen saturation and restoring vital signs to normal ranges.
Smart Images

Figure 2024161366000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the treatment of acute conditions. More specifically, the present invention relates to devices, systems and methods for the treatment of acute conditions. [Background technology]
[0002] Acute disease as referred to herein refers to a rapid deterioration of a subject's physiological condition that may be life-threatening if left untreated. Examples include trauma, sepsis, hemorrhage, severe hemophilia, severe lupus episodes, severe clonal episodes, allograft / autograft rejection, anaphylaxis, and endotoxic shock. As such, these subjects require immediate medical care to alleviate suffering and minimize risk of morbidity and mortality. Treatment of acute disease varies depending on the illness, and depending on the severity of the condition, these treatments are often unsuccessful.
[0003] In contrast, a chronic disease is one that is characterized by a long-term clinical course during which the underlying condition changes little or progresses slowly. Examples include arthritis (such as rheumatoid arthritis), chronic pancreatitis, chronic obstructive pulmonary disease, or chronic heart failure. However, subjects with chronic conditions may also suffer from sudden worsening of the underlying disease course, commonly referred to as acute-on-chronic episodes of the chronic disease. The distinction between acute and chronic diseases is well known in the art.
[0004] The spleen contains half the number of monocytes in the body, making this organ a major source of inflammation, especially in response to endotoxemic shock [1]. The spleen is innervated by different nerve branches, and it has been reported that 98% of the splenic innervation is sympathetic (reviewed in [2]). Electrical stimulation of the splenic nerve is associated with splenic vascular responses [3]. It has been reported that electrical stimulation of the splenic nerve may be useful in the treatment of conditions associated with chronic immune and inflammatory responses (see, for example, references [4, 5, 6, 7]). However, the survival-promoting effects of splenic nerve stimulation in acute illnesses have not been studied.
[0005] There is a need to identify further improved methods of treating acute illnesses. Summary of the Invention [Problem to be solved by the invention]
[0006] The present inventors are the first to demonstrate that neuromodulation of the nerves innervating the spleen, particularly the nerve surrounding the splenic artery (herein referred to as the splenic artery nerve), enhances the survival of animals in an endotoxemic (LPS) shock model. In particular, the present inventors have found that electrical stimulation of the splenic nerve stabilizes the dramatic fall in blood pressure in LPS-treated animals and inhibits the maximum fall in blood pressure. Thus, stimulation of the neural activity of the splenic nerve provides a method for treating acute diseases, particularly life-threatening conditions such as those with physiological changes associated with shock, and cardiovascular dysfunction (such as trauma, hemorrhage, and septic shock). This would be particularly useful, for example, as a one-off treatment in an acute clinical setting. [Means for solving the problem]
[0007] Thus, the present invention provides a method for treating an acute condition, such as trauma, hemorrhage, or septic shock, comprising applying an electrical signal to stimulate neural activity of nerves that innervate the spleen and are associated with a neurovascular bundle (e.g., the splenic artery nerve), the electrical signal improving a physiological parameter indicative of treatment of the acute condition. The improvement in the physiological parameter is any of the group consisting of: restoration of body temperature to between 36 degrees Celsius (°C) and 38°C; restoration of heart rate to 60-100 bpm; restoration of systemic arterial pressure to between 90 / 60 mmHg and 150 / 90 mmHg; restoration of systemic venous pressure to about 5 mmHg in the right atrium and about 8 mmHg in the left atrium; restoration of central venous pressure to a range of about 3-8 mmHg; restoration of pulmonary blood pressure to about 15 mmHg; restoration of respiratory rate to 8-14 breaths per minute; increase in oxygen saturation to 94% or greater; increase in arterial blood oxygen pressure to 12-15 kPa; restoration of arterial blood carbon dioxide pressure to 4.4-6.1 kPa; relief of pain sensation; restoration of urine output to 0.5 ml / kg / hour or greater; increased level of consciousness; reduction in lactate levels; change in blood glucose levels; change in blood base deficit levels; and change in arterial pH levels.
[0008] The present invention also provides a method for treating an acute condition such as trauma, hemorrhage, or septic shock, comprising applying an electrical signal to stimulate neural activity of nerves that innervate the spleen and are associated with a neurovascular bundle (e.g., the splenic artery nerve), the electrical signal improving a physiological parameter indicative of treatment of the acute condition, the improvement of the physiological parameter being any of the group consisting of restoring physiological values of systemic arterial blood pressure between 90 / 60 mmHg and 150 / 90 mmHg and restoring systemic venous pressure in the range of 3 to 8 mmHg, restoring pulmonary blood pressure to about 15 mmHg, restoring lower levels of pulmonary vascular resistance while systemic vascular resistance and pulmonary capillary wedge pressure are increased, elevated levels of lipase are suppressed, elevated levels of amylase are suppressed.
[0009] The present invention also provides a system for stimulating neural activity of a nerve innervating the spleen and associated with a neurovascular bundle (e.g., the splenic artery nerve) to treat an acute condition. The system comprises at least one electrode in signaling contact with the nerve and at least one controller electrically connected to the at least one electrode. The at least one controller is configured to control operation of the at least one electrode to apply an electrical signal to the nerve. The electrical signal is configured to improve a physiological parameter indicative of treatment of the acute condition. The improvement in the physiological parameter is any of the group consisting of: restoration of body temperature to between 36°C and 38°C; restoration of heart rate to 60-100 bpm; restoration of systemic arterial pressure to between 90 / 60 mmHg and 150 / 90 mmHg; restoration of systemic venous pressure to about 5 mmHg in the right atrium and about 8 mmHg in the left atrium; restoration of central venous pressure to a range of about 3-8 mmHg; restoration of pulmonary blood pressure to about 15 mmHg; restoration of respiratory rate to 8-14 breaths per minute; increase in oxygen saturation to 94% or greater; increase in arterial blood oxygen pressure to 12-15 kPa; restoration of arterial blood carbon dioxide pressure to 4.4-6.1 kPa; relief of pain sensation; restoration of urine output to 0.5 ml / kg / hour or greater; increased level of consciousness; reduction in lactate levels; change in blood glucose levels; change in blood base deficit levels; and change in arterial pH levels.
[0010] The present invention also provides a computer-implemented method for treating an acute illness in a subject, the method comprising controlling operation of at least one electrode of the system of the present invention to apply a signal to a nerve innervating the spleen to reversibly stimulate neural activity of the nerve, the nerve being associated with a neurovascular bundle (e.g., the splenic artery nerve).
[0011] The present invention also provides a computer comprising a processor and a non-transitory computer readable storage medium, the non-transitory computer readable storage medium having an executable computer program, the executable computer program comprising code portions which, when loaded and executed by the processor, cause the processor to apply an electrical signal, the electrical signal stimulating neural activity of a nerve innervating the spleen to improve a physiological parameter indicative of treatment of an acute condition, the nerve being associated with a neurovascular bundle (e.g., the splenic artery nerve).
[0012] The present invention also provides a neurostimulatory electrical signal for use in a method for treating an acute condition, the electrical signal being any of the electrical signals described herein.
[0013] The present invention also provides an electrical waveform for use in a method for treating an acute condition, the electrical waveform causing reversible depolarization of neuronal membranes of nerves innervating the spleen, and action potentials being generated de novo within the nerves, the nerves being connected to a neurovascular bundle (e.g., the splenic artery nerve).
[0014] The present invention also provides a charged particle for use in a method for treating an acute disease, the charged particle causing a reversible depolarization of the neuronal membrane of a nerve innervating the spleen, and an action potential is generated de novo in the modified nerve, the nerve being connected to a neurovascular bundle (e.g., the splenic artery nerve).
[0015] The present invention also provides a modified nerve in signal transducing contact with the neural interface of the system of the present invention. The nerve innervates the spleen and is associated with a neurovascular bundle (e.g., the splenic artery nerve). The at least one electrode in signal transducing contact with the nerve distinguishes the nerve from the nerve in its native state. The nerve is present in a subject with an acute illness.
[0016] The present invention also provides modified nerves obtainable by stimulating the neural activity of nerves innervating the spleen, said nerves being connected to the neurovascular bundle, preferably the splenic artery nerve, in the method of the present invention.
[0017] The invention also provides a method of controlling a system of the invention in signal transducing contact with a nerve innervating the spleen, the method comprising transmitting a control command to the system, in response to which the system applies a signal to the nerve, the nerve being associated with a neurovascular bundle (e.g., the splenic artery nerve).
[0018] Detailed Description of the Invention Nerves supplying the spleen The innervation of the spleen is mainly sympathetic or noradrenergic, with peptidergic neurons possibly representing the majority of the remaining neurons. In humans, the spleen is mainly innervated by the splenic plexus, which surrounds the splenic artery. The splenic artery is covered by nerve tissue that originates from the celiac plexus and continues from the splenic artery to the spleen as the splenic plexus. The splenic plexus enters the spleen at the hilum where the splenic artery branches off with terminal branches, and the splenic plexus follows these branches into the splenic parenchyma.
[0019] The splenic plexus includes several nerve bundles, each consisting of a small bundle of nerve fibers, that run from the celiac trunk to the spleen, around the main splenic artery. The nerve bundles that run around the splenic nerve (otherwise known as periarterial nerve bundles) are referred to herein as the splenic nerves.
[0020] The course of the splenic artery is variable. In general, it tends to run along the surface of the pancreas and is often in direct contact with it. Between its origin and its entry point at the hilum, the splenic artery can depart from the surface of the pancreas at certain locations such that it does not come into direct contact with the pancreas.
[0021] The present invention involves modulating the neural activity of a nerve innervating the spleen by applying an electrical signal, where the nerve is associated with a neurovascular bundle, preferably the splenic artery nerve.
[0022]
[0003] In some embodiments, the nerve is a sympathetic nerve.
[0023] In some embodiments, the invention may involve applying an electrical signal to one splenic nerve, hi other embodiments, the invention may involve multiple (i.e., bundles) of splenic nerves.
[0024] In other embodiments, the invention may include applying an electrical signal to at least one of the splenic nerve and the splenic artery, hi other embodiments, the invention may include applying an electrical signal to all of the splenic nerve and the splenic artery.
[0025] In another embodiment, the invention may include applying an electrical signal to at least one splenic nerve, such as the splenic plexus, associated with a portion of the splenic artery remote from the surface of the pancreas. For example, the electrical signal may be applied to at least one nerve at a site adjacent to the splenic artery loop, which is characterized by being remote from the surface of the pancreas by a distance of, for example, 0.5 cm or more, with the intervening space being filled with fatty tissue and / or connective tissue. Applying the electrical signal at this site has the advantage of allowing for a more direct separation of the nerve plexus associated with the splenic artery. This application site is also expected to make the procedure safer in terms of reducing surgical damage to the pancreas.
[0026] In some embodiments, the splenic artery loop is spaced from the surface of the pancreas by a distance of 1 cm or more, for example, the distance between the inner curve of the top of the loop and the surface of the pancreas is about 1 to 2 cm, preferably about 1.5 cm, which may be referred to as the height of the loop as described herein.
[0027] The splenic artery loop may have a neck of about 0.5 cm or more, where "neck" in this context refers to the direct distance between the inner curved surface of the first leg of the loop (where the splenic artery leaves the surface of the spleen) and the inner curved surface of the second leg of the loop (where the splenic artery returns to direct contact with the spleen). In some embodiments, the neck is ≧0.55 cm, ≧0.6 cm, ≧0.65 cm, ≧0.7 cm, ≧0.75 cm, ≧0.8 cm, ≧0.85 cm, ≧0.9 cm, ≧0.95 cm, ≧1 cm, ≧1.1 cm, ≧1.2 cm, ≧1.3 cm, ≧1.4 cm, ≧1.5 cm, ≧1.6 cm, ≧1.7 cm, ≧1.8 cm, ≧1.9 cm, or ≧2.0 cm. In some embodiments, the splenic artery loop may have a neck in the range of about 1.1 cm to about 3.0 cm.
[0028] The number of splenic artery loops can vary between human subjects, but in general there appears to be a positive correlation between the number of splenic artery loops and the age of the subject. Typically, splenic artery loops are more prevalent in human subjects over the age of 45.
[0029] In some embodiments, the signal application sites may be on one or more nerves adjacent to one splenic artery loop.
[0030] In some embodiments, the signal application sites may be on one or more nerves adjacent to multiple splenic artery loops. In some embodiments, each of the multiple independent sites may be stimulated by an independent system or method of the present invention. In some embodiments, each of the multiple aforementioned sites may be stimulated by a single system or device of the method of the present invention.
[0031] In some embodiments, signals may be applied simultaneously, sequentially, or separately to one or more nerves in each of multiple splenic artery loops.
[0032] Simultaneously may mean applying a signal to each of the multiple sites at substantially the same time, i.e. intending to apply a signal to each of the multiple sites at exactly the same time, within possible delay error. Separately may mean applying a signal to each of the multiple sites independently of each other, i.e. the signals are not applied in a consistent order. Each signal is delivered independently to each site. It is understood that application of separate signals may result in each or some of the multiple sites receiving a signal by chance at substantially the same time. Sequentially may mean applying a signal to each of the multiple sites in a defined "order". This may include applying a signal to some of the multiple independent sites at substantially the same time.
[0033] Stimulation of the nerves supplying the spleen The present invention involves applying an electrical signal to a nerve that innervates the spleen, stimulating neural activity in the nerve. The nerve is associated with a neurovascular bundle (e.g., the splenic artery nerve). Stimulation refers to a condition in which signaling activity in at least a portion of the nerve is increased compared to baseline neural activity in that portion of the nerve, where baseline neural activity is the signaling activity of the nerve in a subject before any intervention occurs. In other words, stimulation creates neural activity in that portion of the nerve that results in increased overall neural activity.
[0034] "Neural activity" of a nerve means the signaling activity of the nerve, e.g., the amplitude, frequency, and / or pattern of action potentials in the nerve. The term "pattern" as used herein in the context of action potentials in a nerve is intended to include one or more local field potentials, compound action potentials, population action potentials, and the magnitude, frequency, area under the curve, and other patterns of action potentials in a nerve or subgroups of neurons therein (e.g., fiber bundles).
[0035] Stimulation typically involves increasing neural activity, e.g., generating an action potential in at least a portion of the nerve beyond the point of stimulation. At any point along the axon, a functioning nerve has a distribution of potassium and sodium ions across the nerve cell membrane. The distribution at one point along the axon determines the electrical membrane potential at that point of the axon, which in turn affects the distribution of potassium and sodium ions at adjacent points, which in turn determines the electrical membrane potential of the axon at that point, and so on. This is how a nerve works in its normal state, where action potentials propagate from point to adjacent points along the axon, which can be observed by conventional experimentation.
[0036] One way to characterize the stimulation of nerve activity is the distribution of potassium and sodium ions at one or more points in the axon, which is produced by the application of a temporary external electric field, rather than by the electrical membrane potential at one or more adjacent points of the nerve as a result of the propagating action potential. The temporary external electric field artificially modifies the distribution of potassium and sodium ions in the nerve point, resulting in a depolarization of the nerve cell membrane that would not otherwise occur. The depolarization of the nerve cell membrane caused by the temporary external electric field generates a de novo action potential across that point. This is nerve operation in a disrupted state, which can be observed by the distribution of potassium and sodium ions at the axon point (the point being stimulated) that has an electrical membrane potential that is not influenced or determined by the electrical membrane potential of the adjacent points.
[0037] In this way, stimulation of neural activity continues past the point of signal application and is understood to increase neural activity. Thus, the nerve at the point of signal application is modified because the electric field reversibly depolarizes the nerve cell membrane such that de novo action potentials are generated and propagated to the modified nerve. Thus, the nerve at the point of signal application is modified because de novo action potentials are generated.
[0038] When the signal is an electrical signal, the stimulation is based on the influence of an electric current (e.g., a charged particle, which may be one or more electrons or one or more ions extraneuronally or intraneuronally, at an electrode in signal transducing contact with the nerve) on the distribution of ions across the nerve cell membrane.
[0039] Stimulation of neural activity includes embodiments in which complete stimulation of neural activity in a nerve, ie, total neural activity is increased throughout the nerve.
[0040] The stimulation of neural activity may be partial stimulation. Partial stimulation may be such that the overall signaling activity of the entire nerve is partially increased, or the overall signaling activity of a subset of the nerve fibers of the nerve is completely increased (i.e., there is no neural activity in that subset of the fibers of the nerve), or the overall signaling of a subset of the nerve fibers of the nerve is partially increased, compared to the baseline neural activity of that subset of the fibers of the nerve. For example, the increase in neural activity is ≦5%, ≦10%, ≦15%, ≦20%, ≦25%, ≦30%, ≦35%, ≦40%, ≦45%, ≦50%, ≦60%, ≦70%, ≦80%, ≦90%, or ≦95%, or the neural activity in a subset of the nerve fibers of the nerve is increased. The neural activity may be measured by methods well known in the art, such as the number of action potentials propagating through the axon and / or the amplitude of the local field potential, which reflects the summed activity of the action potentials.
[0041] One advantage of the present invention is that the stimulation of neural activity is reversible. Thus, the modulation of neural activity is not permanent. For example, when application of the signal is discontinued, neural activity at the nerve substantially returns to baseline neural activity within 1-60 seconds, or within 1-60 minutes, or within 1-24 hours (e.g., within 1-12 hours, 1-6 hours, 1-4 hours, 1-2 hours), or within 1-7 days (e.g., within 1-4 days, 1-2 days). In some examples of reversible stimulation, neural activity substantially completely returns to baseline neural activity. That is, the neural activity following cessation of application of the signal is substantially the same as the neural activity before the signal was applied. Thus, the nerve or nerve site regains its normal physiological ability to propagate action potentials.
[0042] In other embodiments, the stimulation of neural activity may be substantially continuous. As used herein, "continuous" is used to mean that the neural activity has a long-term effect. For example, when application of the signal ceases, the neural activity at the nerve remains substantially the same as when the signal was applied, i.e., the neural activity during and after application of the signal is substantially the same. Reversible modulation is preferred.
[0043] Therapeutic Uses The present invention is useful in the treatment of acute conditions, and in particular, the present invention can be used as a last resort intervention. The present invention is particularly useful in the treatment of life threatening conditions and cardiovascular dysfunction that have physiological changes associated with shock.
[0044] Examples of these conditions include trauma, hemorrhage, and shock.
[0045] Trauma includes, for example, physical injuries due to external causes, such as blunt trauma (including motor vehicle crashes, falls, head injuries, lacerations), penetrating trauma (such as amputations, stab wounds, impalement wounds), blast injuries, burns (caused by heat, cold, electricity, chemicals, friction, or radiation), and combinations thereof.
[0046] Hemorrhage is the loss of blood from the circulatory system. Hemorrhage includes, for example, hematemesis (vomiting of fresh blood), hemoptysis (coughing up blood from the lungs), hematuria, cerebral hemorrhage, pulmonary hemorrhage, postpartum hemorrhage, and gastrointestinal hemorrhage. Hemorrhage may result from, for example, traumatic injury or underlying disease. Hemorrhage also includes intraoperative and postoperative hemorrhage.
[0047] Shock includes, for example, septic shock, anaphylactic shock, toxic shock syndrome, cardiogenic shock, hypovolemic shock, and neurogenic shock. The present invention is particularly useful in the treatment of septic shock.
[0048] The present invention is of particular interest in relation to trauma, septic shock, hemorrhage, severe hemophilia, severe episodes of lupus, severe clonal episodes, allograft / graft rejection, anaphylaxis, and endotoxic shock.
[0049] Treatment of a condition can be assessed in a variety of ways, but typically involves determining an improvement in one or more physiological parameters in a subject. As used herein, "improvement in a given physiological parameter" is used in the sense of, with respect to any given physiological parameter, improvement being a change in the value of that parameter in a subject toward a normal value or a normal range of values for that parameter, i.e., toward the value expected in a healthy subject.
[0050] As used herein, "deterioration of a given physiological parameter" refers to any given physiological parameter, where the deterioration means that the change in the value of that parameter in a subject is away from the normal value or the normal range of values for that parameter, i.e., away from the value expected in a healthy subject.
[0051] For example, acute illness may be accompanied by a drop in blood pressure, dizziness or lightheadedness, rash, nausea, muscle pain, shortness of breath, oliguria, muscle pain, and cold, clammy, pale or mottled skin.
[0052] The body's vital signs are particularly useful in assessing acute illnesses, as they are signs that indicate the status of the body's vital (life-sustaining) functions. Vital signs may be one or more of the following: systemic arterial pressure, body temperature, heart rate, respiratory rate, oxygen saturation, and pain sensation.
[0053] Other useful physiological parameters may be systemic venous pressure, pulmonary artery pressure (also referred to herein as pulmonary pressure), hourly urine volume, level of consciousness, arterial oxygen pressure, and arterial carbon dioxide pressure.
[0054] Any one or combination of physiological parameters may be useful in the present invention.
[0055] In subjects with acute illness, improvements in physiological parameters indicative of treatment of the acute illness include: body temperature restored to between 36°C and 38°C (depending on which outlier the subject is exhibiting); heart rate restored to between 60 and 100 bpm; systemic arterial pressure restored to between 90 / 60 mmHg and 150 / 90 mmHg; systemic venous pressure restored to about 5 mmHg in the right atrium and about 8 mmHg in the left atrium; central venous pressure restored to a range of about 3 to 8 mmHg; The physiological parameters may include any one or more of the following: restoration of pulmonary blood pressure, restoration of respiratory rate to 8-14 breaths per minute, increase in oxygen saturation to 94% or more, increase in arterial blood oxygen pressure to 12-15 kPa, restoration of arterial blood carbon dioxide pressure to 4.4-6.1 kPa, relief of pain, restoration of urine output to 0.5 ml / kg / hr or more, increase in level of consciousness, reduction in lactate levels, change in blood glucose levels, change in blood base deficit levels, and change in arterial pH levels. The present invention does not necessarily result in changes in all of these physiological parameters.
[0056] The present invention aims to restore blood pressure (e.g., systemic arterial pressure, systemic venous pressure, central venous pressure, and pulmonary pressure) to the normal range. As known to those skilled in the art, when blood pressure is mentioned in the art, it generally means the arterial pressure in the systemic circulation (i.e., systemic arterial pressure) unless otherwise specified. Normal systemic arterial pressure is considered to be between 90 / 60 mmHg and 120 / 80 mmHg. Systemic arterial pressure values below this range may indicate that the person is suffering from shock. The present invention aims to restore systemic arterial pressure to the normal range. Thus, if the subject is suffering from shock, the present invention aims to increase the systemic arterial pressure.
[0057] Determining systemic venous pressure, central venous pressure, and pulmonary blood pressure may also be useful in the present invention. Determining these pressures typically requires invasive tools such as catheters. However, pulmonary blood pressure may be determined, for example, by ultrasound measurement of the inferior vena cava diameter and apparent cardiac filling pressure. The normal range of systemic venous pressure in a healthy adult is typically 5 mmHg in the right atrium and 8 mmHg in the left atrium. The normal range of central venous pressure in a healthy adult is believed to be within the range of about 3 to 8 mmHg. The normal range of pulmonary blood pressure in a healthy adult is typically about 15 mmHg at rest.
[0058] The present invention also aims to restore body temperature to the normal range, i.e., between 36°C and 38°C.
[0059] A normal heart rate is considered to be between 60 and 100 bpm, but acute illness typically causes the heart rate to increase. The present invention also aims to restore the heart rate to the normal range, i.e., to reduce the heart rate.
[0060] A normal respiratory rate is between 8 and 14 breaths per minute, and the present invention aims to restore the respiratory rate to the normal range.
[0061] A healthy person at sea level will typically have an oxygen saturation (SO2) value between 96% and 99%, with levels usually above 94%. Levels below 90% are considered low and result in hypoxemia. When blood oxygen levels fall below 80 percent, organ function, such as the brain and heart, can be impaired. Prolonged low oxygen levels can cause respiratory or cardiac arrest. Oxygen saturation is commonly measured using pulse oximetry.
[0062] The normal range of arterial blood oxygen partial pressure in a healthy person is usually 12-15 kPa. The normal range of arterial blood carbon dioxide partial pressure is usually 4.4-6.1 kPa. The present invention aims to restore arterial blood oxygen partial pressure and arterial blood oxygen partial pressure to the normal range.
[0063] Normal urinary output for adults is 0.5-1 ml / kg / hour. This corresponds roughly to 30-60 ml per hour for an average sized adult. The present invention aims to restore urinary output to the normal range.
[0064] Further physiological parameters useful in the present invention may include the levels of lactate, blood glucose, blood base deficit and arterial pH, which can be determined by biochemical analysis.
[0065] Those skilled in the art will know any suitable method for determining the numerical value of any parameter.
[0066] Those skilled in the art will appreciate that the baseline of any physiological parameter of a subject need not be a fixed or specific value, but rather may be a mean value that can vary within a normal range or have an associated error and confidence interval. For example, the normal range of a person's vital signs varies with age, weight, sex, and overall health. Suitable methods for determining baseline values are well known to those skilled in the art.
[0067] As used herein, a physiological parameter is determined in a subject when a value of that parameter exhibited by the subject upon detection is determined. A detector (e.g., a physiological sensor subsystem, a physiological data processing module, and a physiological sensor) is any element capable of such a determination. In accordance with the present invention, detecting any of the physiological parameters may occur before, during, and / or after modulation of sympathetic neural activity. Detection may be performed manually by a human (e.g., a clinician or caregiver) with or without the use of a device, such as an instrument, that is not part of the system of the present invention, or with or without the use of a detector that is part of the system of the present invention. When a device or detector is used, detection may occur autonomously.
[0068] Thus, in certain embodiments, the invention further comprises determining one or more physiological parameters of the subject, and the signal is applied only if the determined physiological parameters meet or exceed a predetermined threshold. In such embodiments where more than one physiological parameter of the subject is determined, the signal may be applied if any one of the determined physiological parameters meets or exceeds its threshold, or alternatively, may be applied only if all of the determined physiological parameters meet or exceed their threshold. In certain embodiments where the signal is applied by a system of the invention, the system further comprises at least one detector configured to determine one or more physiological parameters of the subject.
[0069] In certain embodiments of the invention, the one or more detected physiological parameters are one or more of the group consisting of blood pressure (e.g., systemic arterial pressure, systemic venous pressure, and pulmonary blood pressure), body temperature, heart rate, respiratory rate, oxygen saturation, pain sensation, hourly urine volume, level of consciousness, or levels of lactate, blood glucose, base deficit in blood, and / or arterial pH. It is understood that any two physiological parameters may be determined in parallel embodiments, where a controller is connected to detect a pattern of action potential tolerance in the subject.
[0070] For example, in addressing the severity of shock and its response to medical intervention, one important factor is tissue perfusion, which may be increased during the onset of shock. Tissue perfusion may be associated with a fall in blood pressure and a number of other changes in physiological parameters, including lactate and, to a lesser extent, base deficit and arterial pH levels. Some embodiments of the invention aim to restore these to normal levels, as previously described.
[0071] The predefined threshold for a physiological parameter is the minimum (or maximum) value of that parameter that must be exhibited by the subject before a particular therapeutic intervention is applied. For any parameter, the threshold may be defined as a value indicative of a pathological condition or a disease state. The threshold may be defined as a value indicative of the onset of a pathological condition or a disease state. Thus, depending on the predefined threshold, the invention can be used as a treatment. Alternatively, the threshold may be defined as a value indicative of the physiological state of the subject (the subject is, for example, asleep, has eaten, or is exercising). The appropriate value for any physiological parameter should be easily determined by the skilled person (see, for example, standard medical practice).
[0072] Such a threshold for any physiological parameter is exceeded when the value indicated by the subject exceeds a threshold, i.e., when the indicated value deviates more from the normal or healthy value for that physiological parameter by more than the predefined threshold.
[0073] In addition to receiving neuromodulation of the splenic nerve according to the present invention, a subject of the present invention may also receive treatments and / or medications for symptoms. For example, the subject may receive intravenous fluids, intravenous antibiotics (e.g., penicillin, cephalosporin, tetracycline, macrolides, or fluoroquinolones), medications to increase blood pressure and / or blood flow to tissues and organs, surgery to remove sources of infection (such as abscesses) and tissues severely damaged by infection, or, if breathing is extremely difficult, oxygen through a face mask, nasal cannula, or a tube connected to a ventilator (oxygen inhaler) that passes down the throat and into the trachea.
[0074] The subject may also receive anti-inflammatory medication (often continuing medication that was occurring before the system of the present invention was added), including nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, 5ASAs, disease-modifying anti-inflammatory drugs (DMARDs) such as azathioprine, methotrexate, and cyclosporine, biologics such as infliximab and adalimumab, and newer oral DMARDs such as JAK inhibitors.
[0075] Thus, the present invention provides for the use of these treatments and / or drugs in conjunction with the systems of the present invention.
[0076] The proper form of the electrical signal The present invention uses an electrical signal applied via at least one electrode placed in signal transducing contact with a nerve innervating the spleen, the nerve being associated with a neurovascular bundle (e.g., the splenic artery nerve). As used herein, "in signal transducing contact" is when at least a portion of the electrical signal applied via at least one electrode is received by the nerve.
[0077] The electrical signal is preferably provided as a sole treatment, for example in an acute clinical setting, but is not limited to being applied only once. During a sole treatment, the electrical signal may be applied to the nerve continuously or periodically. Preferably, the electrical signal is applied to the nerve until there is an improvement in the subject's physiological parameters.
[0078] The electrical signals applied according to the present invention are ideally non-destructive. As used herein, a "non-destructive signal" is a signal that, when applied, does not irreversibly damage the basic nervous system signal conduction ability of the nerve. That is, application of a non-destructive signal maintains the ability of the nerve or fiber or other nervous tissue to which the signal is applied to conduct an action potential when application of the signal ceases, even if its conduction has in fact been artificially stimulated as a result of application of the non-destructive signal.
[0079] The electrical signal applied in accordance with the present invention may be a voltage or current waveform.
[0080] The electrical signal may be characterized by one or more electrical signal parameters, including waveform, frequency, and amplitude.
[0081] Alternatively or additionally, the electrical signal may be characterized by a pattern of application of the electrical signal to the nerve. The pattern of application is the timing of the application of the electrical signal to the nerve. The pattern of application may be continuous application or periodic application. The pattern of application may include a set period for application of the signal.
[0082] Continuous application refers to when the electrical signal is applied to the nerve in a continuous manner. In embodiments where the electrical signal is a series of pulses, the gaps between these pulses (i.e., between the pulse width and phase duration) do not mean that the signal is not applied continuously.
[0083] Periodic application refers to when an electrical signal is applied to a nerve in a repeating pattern (eg, an on-off pattern).
[0084] waveform Modulation (e.g., stimulation) of nerves innervating the spleen (where the nerves are connected to the neurovascular bundle (e.g., the splenic artery nerve)) can be achieved using electrical signals that serve to replicate the normal neural activity of the nerve. Thus, the waveform of the electrical signal may comprise one or more pulse trains having square, sawtooth, sinusoidal, triangular, trapezoidal, pseudo-trapezoidal, or complex pulses. In other embodiments, the waveform may be a square, sinusoidal, triangular, trapezoidal, pseudo-trapezoidal, or complex waveform. In other embodiments, the waveform may be a constant amplitude waveform.
[0085] The signal may be biphasic. The term "biphasic" refers to a signal that applies both positive and negative charges to a nerve over time.
[0086] A signal may be symmetric or asymmetric. A symmetric signal is one in which the waveform produced when a positive charge is applied to the nerve is symmetric to the waveform produced when a negative charge is applied to the nerve. An asymmetric signal is one in which the waveform produced when a positive charge is applied to the nerve is not symmetric to the waveform produced when a negative charge is applied to the nerve.
[0087] The signal may be charge-balanced. A charge-balanced signal refers to a signal that applies equal (or approximately) amounts of positive and negative charge to the nerve over the duration of the signal.
[0088] amplitude For the purposes of the present invention, amplitude is referred to herein in terms of the charge density per phase. The charge per phase applied to a nerve by an electrical signal is defined as the integral of the current over one phase (e.g., over one phase of a biphasic pulse in the case of a charge-balanced biphasic pulse). Thus, the charge density per phase applied to a nerve by an electrical signal is the charge per phase per unit of contact area between at least one electrode and the nerve, and is also the integral of the current density over one phase of the signal waveform. In other words, the charge density per phase applied to a nerve by an electrical signal is the charge per phase applied to a nerve by an electrical signal divided by the contact area between at least one electrode (typically the cathode) and the nerve.
[0089] The charge density per phase required by the present invention represents the amount of energy required to stimulate neural activity within the nerves innervating the spleen (which are connected to the neurovascular bundle (e.g., the splenic artery nerve)) to improve physiological parameters.
[0090] We have shown that the charge density per phase required to stimulate neural activity in the porcine splenic nerve is approximately 1 cm per phase. 2 Between 5 and 150 μC per cm per phase, or in some cases using an extravascular cuff (electrode design may have a small effect on values). 2 For example, the charge density per phase applied by the electrical signal was found to be between 5 μC and 180 μC per phase. 2 ≦10μC per phase, cm 2≦15μC per phase cm 2 ≦20μC per phase, cm 2 ≦25μC per phase cm 2 ≦30μC per phase, cm 2 ≦40μC per phase, cm 2 ≦50μC per phase, cm 2 ≦75μC per phase cm 2 ≦100μC per phase, cm 2 ≦125μC per phase cm 2 ≦150μC per phase or cm per phase 2 Additionally or alternatively, the charge density per phase applied by the electrical signal may be ≦180 μC per phase cm 2 ≥ 5μC per phase, cm 2 ≥ 10μC per phase, cm 2 ≥ 15μC per phase, cm 2 ≥ 20μC per phase, cm 2 ≥ 25μC per phase, cm 2 ≥ 30μC per phase, cm 2 ≥ 40μC per phase, cm 2 ≥ 50μC per phase, cm 2 ≥ 75μC per phase, cm 2 ≥ 100μC per phase, cm 2 ≥ 125μC per phase or cm per phase 2 Any combination of the above upper and lower limits is also possible.
[0091] The inventors further demonstrated that the suggested estimates of the phase-by-phase charge density required to stimulate neural activity in the human splenic nerve range from about 70 to 1300 μC / cm 2 For example, the charge density per phase applied by the electrical signal was found to be between 1 cm per phase. 2 ≦80μC per phase, cm 2 ≦140μC per phase cm 2 ≦170μC per phase cm 2 ≦230μC per phase, cm 2 ≦250μC per phase, cm 2≦300μC per phase, cm 2 ≦350μC per phase, cm 2 ≦400μC per phase, cm 2 ≦450μC per phase, cm 2 ≦500μC per phase, cm 2 ≦1100μC per phase or cm per phase 2 Additionally or alternatively, the charge density per phase applied by the electrical signal may be ≦1300 μC per phase cm 2 ≥ 70μC per phase, cm 2 ≥ 140μC per phase, cm 2 ≥ 170μC per phase, cm 2 ≥ 230μC per phase cm 2 ≥ 250μC per phase, cm 2 ≥ 300μC per phase, cm 2 ≥ 350μC per phase, cm 2 ≥ 400μC per phase, cm 2 ≥ 450μC per phase, cm 2 ≥ 500μC per phase, cm 2 ≥ 1100μC per phase or cm per phase 2 Any combination of the above upper and lower limits is also possible.
[0092] The total charge applied to a nerve by an electrical signal at any time period is a result of the charge density per phase of the signal, as well as the frequency of the signal, the pattern of application of the signal, and the area of contact between at least one electrode and the nerve, as further described herein.
[0093] Those skilled in the art will appreciate that the amplitude of the applied electrical signal required to achieve the intended stimulation of neural activity will depend on the location of the electrodes and the associated electrophysiological properties (e.g., impedance). It is within the ability of those skilled in the art to determine the appropriate current amplitude to achieve the intended modulation of neural activity in any given subject.
[0094] It is, of course, understood in the art that the electrical signal applied to the nerve will be within clinical safety limits (e.g., suitable for maintaining nerve signal function, suitable for maintaining nerve integrity, and suitable for maintaining subject safety). Electrical parameters within clinical safety limits will typically be determined by preclinical testing.
[0095] periodic application Periodic application refers to an electrical signal being applied to a nerve in a repeating pattern. A preferred repeating pattern is an on-off pattern, where the signal is applied for a first period, referred to herein as the "on" period, stopped for a second period, referred to herein as the "off" period, then again applied for the first period, followed by stopping for the second period, etc.
[0096] The periodic on-off pattern may have an on period between 0.1 and 10 seconds and an off period between 0.5 and 30 seconds. For example, the on period (referring to the time during which pulses of a particular frequency and amplitude are delivered to a nerve) may be ≦0.2 seconds, ≦0.5 seconds, ≦1 second, ≦2 seconds, ≦5 seconds, or 10 seconds. Alternatively or additionally, the on period may be ≧0.1 seconds, ≧0.2 seconds, ≧0.5 seconds, ≧1 second, ≧2 seconds, or ≧5 seconds. Any combination of the above upper and lower limits of the on period is possible. For example, the off period (referring to the time between on periods during which pulses are not delivered to a nerve) may be ≦1 second, ≦3 seconds, ≦5 seconds, ≦10 seconds, ≦15 seconds, ≦20 seconds, ≦25≦, or ≦30 seconds. Alternatively or additionally, the off period may be ≧0.5 seconds, ≧1 second, ≧2 seconds, ≧5 seconds, ≧10 seconds, ≧15 seconds, ≧20 seconds, or ≧25 seconds. Any combination of the above upper and lower limits for the off period is possible.
[0097] Periodic application may also be referred to as duty cycle application. Duty cycle represents the percentage of time that a signal is applied to a nerve for a cycle of a periodic pattern. For example, a 20% duty cycle may represent a periodic pattern having an on-period of 2 seconds and an off-period of 10 seconds. Alternatively, a 20% duty cycle may represent a periodic pattern having an on-period of 1 second and an off-period of 5 seconds. In other words, periodic application may be referred to as on-off pattern stimulation or burst stimulation.
[0098] A suitable duty cycle for the present invention is between 0.1% and 100%.
[0099] period The signal is applied for a specific period of time, where the signal can be applied periodically or continuously. The period of time may be determined by the clinician or may be preset.
[0100] The clinician may terminate the applied signal for a period of time depending on the physiological parameter of the subject. Preferably, the electrical signal is applied to the nerve until there is an improvement in the physiological parameter of the subject.
[0101] In some examples, the time period may be < 1 minute, < 5 minutes, < 10 minutes, < 30 minutes, or < 1 hour. Additionally or alternatively, the time period may be > 1 minute, > 5 minutes, > 10 minutes, or > 30 minutes.
[0102] frequency Frequency is defined as the inverse of the phase duration of the electrical waveform (ie, 1 / phase).
[0103] The inventors have found suitable frequencies for stimulating the nerves that innervate the spleen, which are connected to the neurovascular bundle (e.g., the splenic artery nerve). In particular, the inventors have found suitable frequencies for embodiments in which the electrical signal is applied periodically and for embodiments in which the electrical signal is applied continuously.
[0104] As previously mentioned, embodiments in which electrical signals are applied periodically and embodiments in which electrical signals are applied continuously provide different functionality using different stimulation parameters: Continuous stimulation may be used to induce changes in blood flow within the splenic vasculature that can be detected and used on-table or pre- and post-operatively as an indicator of successful electrode placement and / or amplitude determination, and periodic stimulation may be used as a preferred therapeutic paradigm, thereby avoiding such blood flow changes and / or other potential systemic effects while maintaining therapeutic effectiveness.
[0105] In embodiments where the electrical signal is applied periodically, the frequency of the electrical signal is ≦300 Hz, preferably ≦50 Hz, more preferably ≦10 Hz. For example, the frequency of the electrical signal may be ≦50 Hz, ≦100 Hz, ≦150 Hz, ≦200 Hz, ≦250 Hz, or ≦300 Hz. In other examples, the frequency of the electrical signal may be ≦10 Hz, ≦15 Hz, ≦20 Hz, ≦25 Hz, ≦30 Hz, ≦35 Hz, ≦40 Hz, ≦45 Hz, or ≦50 Hz. In further examples, the frequency may be ≦1 Hz, ≦2 Hz, ≦5 Hz, or ≦10 Hz. Additionally or alternatively, the frequency of the electrical signal may be ≧10 Hz, ≧15 Hz, ≧20 Hz, ≧25 Hz, ≧30 Hz, ≧35 Hz, ≧40 Hz, ≧45 Hz, or ≧50 Hz. In other examples, the frequency of the electrical signal may be ≧0.1 Hz, ≧0.2 Hz, ≧0.5 Hz, ≧1 Hz, ≧2 Hz or ≧5 Hz. Any combination of the above upper and lower limits is also possible.
[0106] In embodiments where the electrical signal is applied continuously, the frequency of the electrical signal is ≦50 Hz, preferably ≦10 Hz, more preferably ≦2 Hz, and even more preferably ≦1 Hz. For example, the frequency may be ≦1 Hz, ≦2 Hz, ≦5 Hz, or ≦10 Hz. In other examples, the frequency may be ≦0.1 Hz, ≦0.2 Hz, ≦0.3 Hz, ≦0.4 Hz, ≦0.5 Hz, ≦0.6 Hz, ≦0.7 Hz, ≦0.8 Hz, or ≦0.9 Hz. Additionally or alternatively, the frequency of the electrical signal may be ≧0.1 Hz, ≧0.2 Hz, ≧0.5 Hz, ≧1 Hz, ≧2 Hz, or ≧5 Hz. Any combination of the above upper and lower limits is possible.
[0107] When the signal waveform consists of a pulse train, the pulses are applied to the nerve at intervals according to the frequency described above. For example, a frequency of 50 Hz would result in 50 pulses being applied to the nerve per second.
[0108] Electrode and neural interface design An electrical signal is applied to a nerve innervating the spleen (the nerve being associated with a neurovascular bundle (e.g., the splenic artery nerve)) via at least one electrode in signal transmitting contact with the nerve, which may be positioned in a neural interface.
[0109] In some embodiments, the electrodes and / or neural interface are configured for placement around at least one splenic nerve and / or around the splenic artery, in such embodiments, the neural interface may be a cuff-type interface or other interfaces that partially or completely avoid the nerve may be used.
[0110] In other embodiments, the neural interface 10 is configured for placement over at least one of the splenic nerve and / or the splenic artery, in such embodiments, the neural interface 10 may be a patch or clip type interface.
[0111] In other embodiments, the neural interface 10 is configured for placement in the splenic artery, in such embodiments, the neural interface may be a catheter or probe type interface.
[0112] In other embodiments, the neural interface 10 is configured for placement on at least one splenic artery nerve, hi such embodiments, the neural interface may be a pin-type interface.
[0113] The neural interface comprises at least one electrode, which may be fabricated from or partially or entirely coated with a high charge capacity material, such as platinum black, iridium oxide, titanium nitride, tantalum, poly(ethylenedioxythiophene), and suitable combinations thereof.
[0114] In some embodiments, the neural interface is suitable for applying an electrical signal to the splenic artery nerve at a location where the splenic artery does not directly contact the pancreas. Applying an electrical signal to the splenic artery nerve at a location where the splenic artery does not directly contact the pancreas has the advantage of the additional space available around the splenic artery, which allows additional freedom in the design of the neural interface 10, and in particular the design of the at least one electrode.
[0115] The at least one electrode may be a flat interface electrode that is flexible to avoid the nerve and / or splenic artery when the neural interface 10 is secured over the nerve, particularly in embodiments where the neural interface is configured for placement on or around at least one splenic nerve and / or splenic artery, although other electrode types are suitable for use with the present invention.
[0116] Other electrode types suitable for the present invention include cuff electrodes (e.g., spiral cuffs, helical cuffs, or flat interfaces), hemi-cuff electrodes, mesh, straight rod-shaped leads, paddle leads or disk contact electrodes (including multi-disk contact electrodes), hook electrodes, sling electrodes, intrafascicular electrodes, glass suction electrodes, paddle electrodes, and percutaneous cylindrical electrodes.
[0117] The at least one electrode may comprise a first electrode 11 and a second electrode 12, referred to herein as a bipolar electrode configuration. Figure 1 shows a schematic diagram of an example bipolar electrode configuration, where the electrodes are placed in signaling contact with at least one splenic nerve and / or splenic artery. As described elsewhere herein, suitable signaling contact may be achieved by placing the electrodes around (i.e., partially or completely avoiding), on the nerve and / or artery, or within the splenic nerve or artery.
[0118] As shown in Figure 1, a first electrode 11 and a second electrode 12 are positioned along the longitudinal axis of the nerve. An electrical signal may be applied to the electrodes such that the first electrode 11 is the anode and the second electrode 12 is the cathode. Alternatively, the first electrode 11 may be the cathode and the second electrode 12 may be the anode.
[0119] In other embodiments, the at least one electrode may comprise a first electrode, a second electrode, and a third electrode, referred to herein as a tripolar electrode configuration.
[0120] As in a bipolar configuration, the first, second, and third electrodes may be positioned along the long axis of the nerve, and in one example, the second electrode may be positioned between the first and third electrodes.
[0121] The electrodes may be at least partially insulated from one another by non-conductive biocompatible material. To achieve this goal, the neural interface may comprise non-conductive biocompatible material that is spaced laterally along the nerve when the device is in use.
[0122] The inventors have found that the preferred electrode size for applying an electrical signal to at least one splenic nerve is 0.1 to 0.3 mm2 in total surface area. 2 Preferably, the total surface area of the electrodes is 0.2 cm 2 is less than.
[0123] In a preferred electrode configuration, the width of each of the first electrode 11 and second electrode 12 may be between 1 and 4 mm. For example, the width may be between 1 mm and 3 mm, or between 2 mm and 4 mm, or between 2 mm and 3 mm.
[0124] Control Unit 7, the system 50 of the present invention, which may comprise a neural interface, may also comprise at least one controller, e.g., a microprocessor 60, electrically connected to at least one electrode of the neural interface 10 and configured to control the operation of the at least one electrode. The at least one controller may be responsible for triggering the initiation and / or termination of a signal delivered to a nerve by the at least one electrode. Optionally, the at least one controller may be responsible for generating and / or controlling signal parameters.
[0125] At least one control unit is configured to operate in an open loop manner, whereby a predetermined signal is delivered to the nerve via an external trigger (as described above).
[0126] The at least one control is preferably configured to generate, in use, a pre-defined and / or operator-selectable signal that is independent of any inputs in the system 50. The pre-defined and / or operator-selectable signal may be any one of the electrical signals described above. In other embodiments, the at least one control is responsive to an external signal, more preferably information (e.g., data) related to one or more physiological parameters of the subject, but still within the scope of the signals described above.
[0127] The at least one controller may be a microprocessor 60 in a system 50 suitable for insertion into a subject.
[0128] Alternatively or additionally, at least one control may be a control external to the subject.
[0129] At least one control unit may be triggered in response to receiving a signal generated by an operator, such as a physician or a subject into which the device 106 is inserted. To that end, the system 50 may additionally comprise an external system 80 comprising a control unit 101. An example of such a system is described below with reference to FIG.
[0130] The external system 80 of the broader system 100 is external to the system 50 and to the subject and comprises a controller 101. The controller 101 may be used to control and / or externally power the system 50. To this end, the controller 101 may comprise a power device 102 and / or a programming unit 103. The external system 80 may further comprise a power transfer antenna 104 and a data transfer antenna 105, as described further below.
[0131] At least one controller, including microprocessor 60 and controller 101, may be a processor connected to a memory (i.e., a non-transitory computer readable storage medium) having an executable computer program with code portions that, when loaded and executed by the processor, cause the processor to at least control the operation of at least one electrode. By controlling the operation, it is meant that at least one controller causes at least one electrode to apply an electrical signal to a nerve using any of the signal parameters and application patterns described above.
[0132] Neurostimulation systems In addition to the neural interface 10 and the at least one controller, the system 50 may include a signal generator 113 configured to deliver the above-mentioned electrical signal to the at least one electrode in response to control operations from the at least one controller. The signal generator may include at least one current or voltage source.
[0133] The signal generator 113 may be electrically connected to the at least one controller and the at least one electrode. In some embodiments, the at least one electrode may be connected to the signal generator 113 via an electrical lead 107. In some embodiments, the electrical lead may be connected to an interconnector as described above. Alternatively, the signal generator 113 may be directly integrated with the at least one electrode without a lead. In any case, the system 50 may include a device 106 that may be inserted into the subject and may include a DC current blocking output circuit (or an AC current blocking output circuit), optionally based on a capacitor and / or an inductor, for all output channels (e.g., output to at least one electrode or physiological sensor 111).
[0134] In addition to the neural interface 10, at least one electrode, at least one controller, and signal generator 113, system 50 may include one or more of the following components: an insertable transceiver 110, a power source 112, a memory 114 (also referred to as a non-transitory computer readable storage device), a physiological sensor 111, and a physiological data processing module 115. The physiological sensor 111 and the physiological data processing module 115 are referred to herein as a detector.
[0135] The various components of system 50 are preferably part of a single physical device, either sharing a common housing or being a physically separate collection of interconnected components connected by electrical leads, as shown in FIG. 8. Alternatively, however, the present invention may employ systems in which the components are physically separate and communicate wirelessly. Thus, for example, at least one electrode and an insertable device (e.g., insertable device 106) may be part of a single device, or together may form a system (e.g., system 50). In both cases, additional components may be present to form a broader system (e.g., system 100).
[0136] For example, in some embodiments, one or more of the following components may be included in the insertable device 106: a power source 112, a memory 114, and a physiological data processing module 115.
[0137] The power source 112 may comprise a current and / or voltage source for providing power for the signal generator 113. The power source 112 may provide power for the insertable device 106 and / or other components of the system 50, such as the microprocessor 60, the memory 114, and the insertable transceiver 110. The power source 112 may comprise a battery, which may be rechargeable.
[0138] It will be appreciated that the availability of power in an insertable device is limited and the present invention has been conceived with this constraint in mind. The insertable device 106 and / or system 50 may be powered by an inductive power supply or a rechargeable power source.
[0139] The memory 114 may store data relating to the power data and one or more physiological parameters. For example, the memory 114 may store data relating to one or more signals indicative of one or more physiological parameters detected by the detector (e.g., one or more corresponding physiological parameters determined via the physiological sensor 111 and / or via the physiological data processing module 115). Additionally or alternatively, the memory 114 may store data relating to the power data and one or more physiological parameters from the external system 80 via the insertable transceiver 110. To achieve this goal, the insertable transceiver 110 may form part of a communications subsystem of the broader system 100, as described further below.
[0140] The physiological data processing module 115 is configured to process one or more signals indicative of one or more physiological parameters detected by the physiological sensor 111 to determine one or more corresponding physiological parameters. The physiological data processing module 115 may be configured to reduce a size of data associated with the one or more physiological parameters for storage in the memory 114 and / or transmission to an external system via the insertable transceiver 110. The insertable transceiver 110 may include one or more antennas. The insertable transceiver 100 may use any suitable signal processing, such as RF, wireless, infrared, etc., to transmit signals outside the body, e.g., the broader system 100 of which the system 50 is a part.
[0141] Alternatively or additionally, the physiological data processing module 115 may be configured to process signals indicative of one or more physiological parameters and / or process the determined one or more physiological parameters to determine disease progression in the subject.
[0142] The physiological data processing module 115 and at least one physiological sensor 111 may form a physiological sensor subsystem, also known herein as a detection portion, either as part of the system 50, as part of the insertable device 106, or external to the system.
[0143] There may be at least one detector configured to detect one or more physiological parameters related to the treatment. For example, the detector may be configured to detect biomolecule concentrations using electrical, RF or optical (visible, infrared) biochemical sensors.
[0144] The memory 114 may store physiological data related to normal levels of one or more physiological parameters. The data may be collected from various tests specific to the subject in which the system 50 is inserted and known in the art. Upon receiving a signal indicative of a physiological parameter received from the physiological sensor 111, or periodically or upon request from the physiological sensor 111, the physiological data processor 115 may compare the physiological parameter determined from the signal received from the physiological sensor 111 with data related to normal levels of the physiological parameter stored in the memory 114 to determine whether the received signal indicates a deficiency or excess of the particular physiological parameter and thus an evolution of a disease in the subject.
[0145] The microprocessor 60 may be initiated in response to receiving a signal generated by an operator (e.g., a physician or a subject into which the system 50 is inserted). To that end, the system 50 may be part of a broader system 100 that includes an external system 80 and a control unit 101, as described further below.
[0146] Beyond Neurostimulation Systems Neural stimulation system 50 may be part of a broader system 100 that includes multiple subsystems, such as an external system 80, as shown in FIGURE 8. External system 80 may be used to power and program neural stimulation system 50 through the human skin and underlying tissue.
[0147] In addition to the controller 101, the external subsystem 80 may include one or more programming units 103 configured to communicate with one or more power devices 102 and insertable transceivers 110 for wirelessly recharging batteries of a power source 112 used to power the insertable device 106. The programming units 103 and the insertable transceivers 110 may form a communications subsystem. In some embodiments, the power devices 102 are housed together with the programming units 103. In other embodiments, they may be housed in separate devices.
[0148] The external subsystem 80 may also include one or more of a power transfer antenna 104 and a data transfer antenna 105. The power transfer antenna 104 may be configured to transmit an electromagnetic field at a low frequency (e.g., 30 kHz to 10 MHz). The data transfer antenna 105 may be configured to transmit data for programming or reprogramming the insertable device 106 and may be used in addition to the power transfer antenna 104 to transmit an electromagnetic field at a high frequency (e.g., 1 MHz to 10 GHz). At least one antenna of the insertable transceiver 110 may be configured to receive power from an external electromagnetic field generated by the power transfer antenna 104, which may be used to charge a rechargeable battery of the power source 112.
[0149] The power transfer antenna 104, the data transfer antenna 105, and at least one antenna of the insertable transceiver 110 have certain characteristics such as a resonant frequency and a quality factor (Q). One implementation of the antenna is a coil of wire with or without a ferrite core forming an inductor with a given inductance. This inductor may be connected to a resonant capacitor and a resistive loss to form a resonant circuit. The frequency is set to match the frequency of the electromagnetic field generated by the power transfer antenna 105. A second antenna of the at least one antenna of the insertable transceiver 110 can be used within the system 50 for receiving data from and transmitting data to the external system 80. When multiple antennas are used in the system 50, they are rotated 30 degrees from each other to achieve a better degree of power transfer efficiency during a slight offset with the power transfer antenna 104.
[0150] The external system 80 may include one or more externally worn physiological sensors 121 (not shown) to detect signals indicative of one or more physiological parameters. The signals may be transmitted to the system 50 via at least one antenna of the insertable transceiver 110. Alternatively or additionally, the signals may be transmitted to the external system 50 and then transmitted to the system 50 via at least one antenna of the insertable transceiver 110.
[0151] For example, in certain embodiments, the external detector of the insertable device may include a non-invasive blood flow monitor, such as an ultrasonic flow meter, and / or a non-invasive blood pressure monitor, to determine changes in physiological parameters, in particular the physiological parameters mentioned above.
[0152] The system 100 may have a safeguard feature that will discontinue electrical stimulation of the nerve in the following example events: abnormal operation of the system 50 (e.g., overvoltage), abnormal readings from the inserted physiological sensor 111 (e.g., a temperature increase of more than 2 degrees Celsius or excessively high or low electrical impedance at the electrode-tissue interface), abnormal readings from the externally worn physiological sensor 121 (not shown), or detection of an abnormal response to stimulation by an operator (e.g., physician or subject). The safeguard feature may be implemented via the controller 101 and communicated to or internally within the system 50.
[0153] The external system 80 may include an actuator 120 (not shown) that, when pressed by an operator (e.g., a physician or subject), delivers a signal via the control unit 101 and each communication subsystem, triggering the microprocessor 60 of the system 50 to deliver a signal to a nerve via at least one electrode.
[0154] The external system 80 may include a display 109 for the microcontroller 60 or control unit 101 to alert an operator (e.g., a physician or the subject) about the state of the system or the subject. The display 109 may be a monitor, such as an LED monitor, or may be a visual indicator, such as an LED.
[0155] The system 100 of the present invention, including the external system 80, and in particular the system 50, is preferably made or coated with a biostable and biocompatible material. This means that the system is protected from damage due to exposure to body tissues and minimizes the risk of the system eliciting an unfavorable reaction by the host that may ultimately lead to rejection. The material used to make or coat the system should ideally be resistant to the formation of biofilms. Suitable materials include, but are not limited to, poly(3,4-ethylenedioxythiophene):p-toluenesulfonate (PEDOT:PTS or PEDT), poly(p-xylylene) polymer (known as parylene), and polytetrafluoroethylene.
[0156] The insertable device 50 of the present invention typically weighs less than 50 g.
[0157] General The methods described herein may be implemented by software in machine-readable form on a tangible storage medium, such as in the form of a computer program comprising computer program code means adapted to perform all of the methods described herein when the program is executed on a computer, where the computer program may be embodied on a computer readable recording medium. Examples of tangible (or non-transitory) storage media include disks, thumb drives, memory cards, and the like, but do not include propagated signals. The software may be suitable for execution on parallel or serial processors, such that the methods may be performed in any suitable order or simultaneously. This recognizes that firmware and software may be valuable and separately tradable items. It is intended to include software that operates on or controls "dumb" or standard hardware to perform a desired function. It is also intended to include software that "describes" or defines the configuration of hardware, such as HDL (Hardware Description Language) software, which is used to design silicon chips or configure universal programmable chips to perform a desired function.
[0158] Those skilled in the art will recognize that storage devices used to store program instructions can be distributed across a network. For example, a remote computer may store an example of a process written as software. A local or terminal computer may access a remote computer and download some or all of the software that executes the program. Alternatively, a local computer may download parts of the software as needed, or execute some software instructions at a local terminal and some at a remote computer (or computer network). Those skilled in the art will also recognize that all or part of the software instructions may be executed by dedicated circuitry such as DSPs, programmable logic arrays, etc., utilizing conventional techniques known to those skilled in the art.
[0159] Unless otherwise indicated, each embodiment described herein may be combined with any other embodiment described herein. The term "comprising" includes "including" and "consisting of," e.g., a composition "comprising" X may consist exclusively of X or may include something additional, e.g., X+Y.
[0160] It will be appreciated that the benefits and advantages described above may relate to one embodiment or to several embodiments, and an embodiment is not limited to one that solves some or all of the problems described above or has some or all of the benefits and advantages described above.
[0161] The above preferred embodiments are given by way of example only, and it will be appreciated that various modifications may be made by those skilled in the art. Although various embodiments have been described above with a certain degree of particularity or with reference to one or more individual embodiments, it will be appreciated that those skilled in the art could make numerous modifications to the disclosed embodiments without departing from the scope of the invention. [Brief description of the drawings]
[0162] Embodiments of the invention will now be described, by way of example, with reference to the following drawings, in which: [Figure 1] 1 illustrates a neural stimulation system. [Diagram 2] 1 illustrates a broader system that includes a neural stimulation system. [Diagram 3] Schematic diagram of the left flank of a pig highlighting the anatomical features of the splenic plexus (spleen, nerve, artery, and vein). The placement of the cuff during periarterial splenic nerve (SpN) stimulation experiments is indicated. The nerve is shown in black, and the artery and vein are shown in grey. [Figure 4A]Figure 4 shows the anatomical and histological analysis of the SpNs and short gastroepiploic arteries along the main SpA (splenic artery). Figure 4A is a schematic diagram of the splenic nerve structure highlighting (dashed line) the area where histological analysis was performed. Figures 4B-4D show sections of the SpNs at different levels as the H&E stained main splenic artery (Figure 4B), short gastric (SG) artery (Figure 4C), and gastroepiploic (GEP) artery (Figure 4D). Nerves in Figures 4C and 4D are indicated by arrows. In Figure 4D, the inset shows the caption of a higher magnification of one nerve bundle. Figure 4E shows box plots reporting the quantification of the number of SpN bundles in different locations (upper panel) and the distribution of their mean diameter in different locations (lower panel). Figure 4F shows the number of bundles in different locations and their relative mean diameter. [Figure 4B] Figure 4 shows the anatomical and histological analysis of the SpNs and short gastroepiploic arteries along the main SpA (splenic artery). Figure 4A is a schematic diagram of the splenic nerve structure highlighting (dashed line) the area where histological analysis was performed. Figures 4B-4D show sections of the SpNs at different levels as the H&E stained main splenic artery (Figure 4B), short gastric (SG) artery (Figure 4C), and gastroepiploic (GEP) artery (Figure 4D). Nerves in Figures 4C and 4D are indicated by arrows. In Figure 4D, the inset shows the caption of a higher magnification of one nerve bundle. Figure 4E shows box plots reporting the quantification of the number of SpN bundles in different locations (upper panel) and the distribution of their mean diameter in different locations (lower panel). Figure 4F shows the number of bundles in different locations and their relative mean diameter. [Figure 4C]Figure 4 shows the anatomical and histological analysis of the SpNs and short gastroepiploic arteries along the main SpA (splenic artery). Figure 4A is a schematic diagram of the splenic nerve structure highlighting (dashed line) the area where histological analysis was performed. Figures 4B-4D show sections of the SpNs at different levels as the H&E stained main splenic artery (Figure 4B), short gastric (SG) artery (Figure 4C), and gastroepiploic (GEP) artery (Figure 4D). Nerves in Figures 4C and 4D are indicated by arrows. In Figure 4D, the inset shows the caption of a higher magnification of one nerve bundle. Figure 4E shows box plots reporting the quantification of the number of SpN bundles in different locations (upper panel) and the distribution of their mean diameter in different locations (lower panel). Figure 4F shows the number of bundles in different locations and their relative mean diameter. [Figure 4D] Figure 4 shows the anatomical and histological analysis of the SpNs and short gastroepiploic arteries along the main SpA (splenic artery). Figure 4A is a schematic diagram of the splenic nerve structure highlighting (dashed line) the area where histological analysis was performed. Figures 4B-4D show sections of the SpNs at different levels as the H&E stained main splenic artery (Figure 4B), short gastric (SG) artery (Figure 4C), and gastroepiploic (GEP) artery (Figure 4D). Nerves in Figures 4C and 4D are indicated by arrows. In Figure 4D, the inset shows the caption of a higher magnification of one nerve bundle. Figure 4E shows box plots reporting the quantification of the number of SpN bundles in different locations (upper panel) and the distribution of their mean diameter in different locations (lower panel). Figure 4F shows the number of bundles in different locations and their relative mean diameter. [Figure 4E]Figure 4 shows the anatomical and histological analysis of the SpNs and short gastroepiploic arteries along the main SpA (splenic artery). Figure 4A is a schematic diagram of the splenic nerve structure highlighting (dashed line) the area where histological analysis was performed. Figures 4B-4D show sections of the SpNs at different levels as the H&E stained main splenic artery (Figure 4B), short gastric (SG) artery (Figure 4C), and gastroepiploic (GEP) artery (Figure 4D). Nerves in Figures 4C and 4D are indicated by arrows. In Figure 4D, the inset shows the caption of a higher magnification of one nerve bundle. Figure 4E shows box plots reporting the quantification of the number of SpN bundles in different locations (upper panel) and the distribution of their mean diameter in different locations (lower panel). Figure 4F shows the number of bundles in different locations and their relative mean diameter. [Figure 4F] Figure 4 shows the anatomical and histological analysis of the SpNs and short gastroepiploic arteries along the main SpA (splenic artery). Figure 4A is a schematic diagram of the splenic nerve structure highlighting (dashed line) the area where histological analysis was performed. Figures 4B-4D show sections of the SpNs at different levels as the H&E stained main splenic artery (Figure 4B), short gastric (SG) artery (Figure 4C), and gastroepiploic (GEP) artery (Figure 4D). Nerves in Figures 4C and 4D are indicated by arrows. In Figure 4D, the inset shows the caption of a higher magnification of one nerve bundle. Figure 4E shows box plots reporting the quantification of the number of SpN bundles in different locations (upper panel) and the distribution of their mean diameter in different locations (lower panel). Figure 4F shows the number of bundles in different locations and their relative mean diameter. [Figure 5A]Figure 5 shows the histological and electrophysiological characterization of the porcine splenic nerve. Figure 5A is a photomicrograph of a semi-ultrathin section (0.5 μm thick) of SpA / SpN stained with toluidine blue. No myelinated axons can be observed in the image. Figure 5B shows traces of evoked compound action potentials (eCAPs) recorded from a periarterial splenic nerve fascicle dissected from an artery when stimulated at 1 Hz using a periarterial cuff (around the entire SpN plexus) or a small cuff around a few fascicles of the SpN bundle. Traces are the average of 10 responses. Figure 5C shows the range of conduction velocities of the different components of the eCAP. Figures 5D and 5E show the strength-duration curves of the SpN obtained by stimulating the whole plexus (Figure 5D) or a few dissected fascicles (Figure 5E). The graphs also show the relative charge densities to obtain eCAP thresholds at different stimulation amplitudes. All stimulation was performed at 1 Hz to limit nerve slowing of conduction of stimulation-evoked action potentials. [Figure 5B] Figure 5 shows the histological and electrophysiological characterization of the porcine splenic nerve. Figure 5A is a photomicrograph of a semi-ultrathin section (0.5 μm thick) of SpA / SpN stained with toluidine blue. No myelinated axons can be observed in the image. Figure 5B shows traces of evoked compound action potentials (eCAPs) recorded from a periarterial splenic nerve fascicle dissected from an artery when stimulated at 1 Hz using a periarterial cuff (around the entire SpN plexus) or a small cuff around a few fascicles of the SpN bundle. Traces are the average of 10 responses. Figure 5C shows the range of conduction velocities of the different components of the eCAP. Figures 5D and 5E show the strength-duration curves of the SpN obtained by stimulating the whole plexus (Figure 5D) or a few dissected fascicles (Figure 5E). The graphs also show the relative charge densities to obtain eCAP thresholds at different stimulation amplitudes. All stimulation was performed at 1 Hz to limit nerve slowing of conduction of stimulation-evoked action potentials. [Figure 5C]Figure 5 shows the histological and electrophysiological characterization of the porcine splenic nerve. Figure 5A is a photomicrograph of a semi-ultrathin section (0.5 μm thick) of SpA / SpN stained with toluidine blue. No myelinated axons can be observed in the image. Figure 5B shows traces of evoked compound action potentials (eCAPs) recorded from a periarterial splenic nerve fascicle dissected from an artery when stimulated at 1 Hz using a periarterial cuff (around the entire SpN plexus) or a small cuff around a few fascicles of the SpN bundle. Traces are the average of 10 responses. Figure 5C shows the range of conduction velocities of the different components of the eCAP. Figures 5D and 5E show the strength-duration curves of the SpN obtained by stimulating the whole plexus (Figure 5D) or a few dissected fascicles (Figure 5E). The graphs also show the relative charge densities to obtain eCAP thresholds at different stimulation amplitudes. All stimulation was performed at 1 Hz to limit nerve slowing of conduction of stimulation-evoked action potentials. [Figure 5D] Figure 5 shows the histological and electrophysiological characterization of the porcine splenic nerve. Figure 5A is a photomicrograph of a semi-ultrathin section (0.5 μm thick) of SpA / SpN stained with toluidine blue. No myelinated axons can be observed in the image. Figure 5B shows traces of evoked compound action potentials (eCAPs) recorded from a periarterial splenic nerve fascicle dissected from an artery when stimulated at 1 Hz using a periarterial cuff (around the entire SpN plexus) or a small cuff around a few fascicles of the SpN bundle. Traces are the average of 10 responses. Figure 5C shows the range of conduction velocities of the different components of the eCAP. Figures 5D and 5E show the strength-duration curves of the SpN obtained by stimulating the whole plexus (Figure 5D) or a few dissected fascicles (Figure 5E). The graphs also show the relative charge densities to obtain eCAP thresholds at different stimulation amplitudes. All stimulation was performed at 1 Hz to limit nerve slowing of conduction of stimulation-evoked action potentials. [Figure 5E]Figure 5 shows the histological and electrophysiological characterization of the porcine splenic nerve. Figure 5A is a photomicrograph of a semi-ultrathin section (0.5 μm thick) of SpA / SpN stained with toluidine blue. No myelinated axons can be observed in the image. Figure 5B shows traces of evoked compound action potentials (eCAPs) recorded from a periarterial splenic nerve fascicle dissected from an artery when stimulated at 1 Hz using a periarterial cuff (around the entire SpN plexus) or a small cuff around a few fascicles of the SpN bundle. Traces are the average of 10 responses. Figure 5C shows the range of conduction velocities of the different components of the eCAP. Figures 5D and 5E show the strength-duration curves of the SpN obtained by stimulating the whole plexus (Figure 5D) or a few dissected fascicles (Figure 5E). The graphs also show the relative charge densities to obtain eCAP thresholds at different stimulation amplitudes. All stimulation was performed at 1 Hz to limit nerve slowing of conduction of stimulation-evoked action potentials. [Figure 6A]Figure 6 shows the transient changes in mSpA BF, mSpV BF, sMABP and HR resulting from SpN stimulation, which are stimulus intensity dependent. Figure 6A shows the average (n=8) changes in mSpA BF (-30 to +180 seconds relative to the start of stimulation) during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figure 6B shows the maximum decrease in mSpA BF reached during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes. Each line represents a tested animal. Figure 6C shows the average (n>3) maximum decrease in mSpA BF reached during 1 min stimulation (symmetric biphasic pulse, PW 400 μs or 200 μs at 10 Hz) of the SpN plexus with different current amplitudes and two different PWs: 400 (filled circles) and 200 (filled squares) μs. Figure 6D shows the changes in mSpV BF (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 12 mA). Figure 6E shows the average (n=3) changes in sMABP and HR (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figures 6F and 6G summarize the mean (n=3) maximum changes in mSpA BF, sMABP, HR, and RR during 1 min of stimulation (symmetric biphasic pulses, PW400 μs at 10 Hz) of the SpN plexus (Figure 6F) or several dissected SpN bundles (Figure 6G) at different current amplitudes. Both graphs show the amplitude (measured peak to peak) of the recorded eCAP (expressed as % relative to the maximum response). The change in SpA BF is expressed as % as the maximum decrease from baseline, the change in HR is expressed as beats per minute (bpm), the change in sMABP is expressed as mmHg, and the change in RR is expressed as respiratory rates per minute (bpm). The two graphs also report the charge density per phase with respect to the stimulation amplitude used. [Figure 6B]Figure 6 shows the transient changes in mSpA BF, mSpV BF, sMABP and HR resulting from SpN stimulation, which are stimulus intensity dependent. Figure 6A shows the average (n=8) changes in mSpA BF (-30 to +180 seconds relative to the start of stimulation) during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figure 6B shows the maximum decrease in mSpA BF reached during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes. Each line represents a tested animal. Figure 6C shows the average (n>3) maximum decrease in mSpA BF reached during 1 min stimulation (symmetric biphasic pulse, PW 400 μs or 200 μs at 10 Hz) of the SpN plexus with different current amplitudes and two different PWs: 400 (filled circles) and 200 (filled squares) μs. Figure 6D shows the changes in mSpV BF (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 12 mA). Figure 6E shows the average (n=3) changes in sMABP and HR (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figures 6F and 6G summarize the mean (n=3) maximum changes in mSpA BF, sMABP, HR, and RR during 1 min of stimulation (symmetric biphasic pulses, PW400 μs at 10 Hz) of the SpN plexus (Figure 6F) or several dissected SpN bundles (Figure 6G) at different current amplitudes. Both graphs show the amplitude (measured peak to peak) of the recorded eCAP (expressed as % relative to the maximum response). The change in SpA BF is expressed as % as the maximum decrease from baseline, the change in HR is expressed as beats per minute (bpm), the change in sMABP is expressed as mmHg, and the change in RR is expressed as respiratory rates per minute (bpm). The two graphs also report the charge density per phase with respect to the stimulation amplitude used. [Figure 6C]Figure 6 shows the transient changes in mSpA BF, mSpV BF, sMABP and HR resulting from SpN stimulation, which are stimulus intensity dependent. Figure 6A shows the average (n=8) changes in mSpA BF (-30 to +180 seconds relative to the start of stimulation) during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figure 6B shows the maximum decrease in mSpA BF reached during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes. Each line represents a tested animal. Figure 6C shows the average (n>3) maximum decrease in mSpA BF reached during 1 min stimulation (symmetric biphasic pulse, PW 400 μs or 200 μs at 10 Hz) of the SpN plexus with different current amplitudes and two different PWs: 400 (filled circles) and 200 (filled squares) μs. Figure 6D shows the changes in mSpV BF (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 12 mA). Figure 6E shows the average (n=3) changes in sMABP and HR (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figures 6F and 6G summarize the mean (n=3) maximum changes in mSpA BF, sMABP, HR, and RR during 1 min of stimulation (symmetric biphasic pulses, PW400 μs at 10 Hz) of the SpN plexus (Figure 6F) or several dissected SpN bundles (Figure 6G) at different current amplitudes. Both graphs show the amplitude (measured peak to peak) of the recorded eCAP (expressed as % relative to the maximum response). The change in SpA BF is expressed as % as the maximum decrease from baseline, the change in HR is expressed as beats per minute (bpm), the change in sMABP is expressed as mmHg, and the change in RR is expressed as respiratory rates per minute (bpm). The two graphs also report the charge density per phase with respect to the stimulation amplitude used. [Figure 6D]Figure 6 shows the transient changes in mSpA BF, mSpV BF, sMABP and HR resulting from SpN stimulation, which are stimulus intensity dependent. Figure 6A shows the average (n=8) changes in mSpA BF (-30 to +180 seconds relative to the start of stimulation) during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figure 6B shows the maximum decrease in mSpA BF reached during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes. Each line represents a tested animal. Figure 6C shows the average (n>3) maximum decrease in mSpA BF reached during 1 min stimulation (symmetric biphasic pulse, PW 400 μs or 200 μs at 10 Hz) of the SpN plexus with different current amplitudes and two different PWs: 400 (filled circles) and 200 (filled squares) μs. Figure 6D shows the changes in mSpV BF (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 12 mA). Figure 6E shows the average (n=3) changes in sMABP and HR (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figures 6F and 6G summarize the mean (n=3) maximum changes in mSpA BF, sMABP, HR, and RR during 1 min of stimulation (symmetric biphasic pulses, PW400 μs at 10 Hz) of the SpN plexus (Figure 6F) or several dissected SpN bundles (Figure 6G) at different current amplitudes. Both graphs show the amplitude (measured peak to peak) of the recorded eCAP (expressed as % relative to the maximum response). The change in SpA BF is expressed as % as the maximum decrease from baseline, the change in HR is expressed as beats per minute (bpm), the change in sMABP is expressed as mmHg, and the change in RR is expressed as respiratory rates per minute (bpm). The two graphs also report the charge density per phase with respect to the stimulation amplitude used. [Figure 6E]Figure 6 shows the transient changes in mSpA BF, mSpV BF, sMABP and HR resulting from SpN stimulation, which are stimulus intensity dependent. Figure 6A shows the average (n=8) changes in mSpA BF (-30 to +180 seconds relative to the start of stimulation) during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figure 6B shows the maximum decrease in mSpA BF reached during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes. Each line represents a tested animal. Figure 6C shows the average (n>3) maximum decrease in mSpA BF reached during 1 min stimulation (symmetric biphasic pulse, PW 400 μs or 200 μs at 10 Hz) of the SpN plexus with different current amplitudes and two different PWs: 400 (filled circles) and 200 (filled squares) μs. Figure 6D shows the changes in mSpV BF (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 12 mA). Figure 6E shows the average (n=3) changes in sMABP and HR (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figures 6F and 6G summarize the mean (n=3) maximum changes in mSpA BF, sMABP, HR, and RR during 1 min of stimulation (symmetric biphasic pulses, PW400 μs at 10 Hz) of the SpN plexus (Figure 6F) or several dissected SpN bundles (Figure 6G) at different current amplitudes. Both graphs show the amplitude (measured peak to peak) of the recorded eCAP (expressed as % relative to the maximum response). The change in SpA BF is expressed as % as the maximum decrease from baseline, the change in HR is expressed as beats per minute (bpm), the change in sMABP is expressed as mmHg, and the change in RR is expressed as respiratory rates per minute (bpm). The two graphs also report the charge density per phase with respect to the stimulation amplitude used. [Figure 6F]Figure 6 shows the transient changes in mSpA BF, mSpV BF, sMABP and HR resulting from SpN stimulation, which are stimulus intensity dependent. Figure 6A shows the average (n=8) changes in mSpA BF (-30 to +180 seconds relative to the start of stimulation) during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figure 6B shows the maximum decrease in mSpA BF reached during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes. Each line represents a tested animal. Figure 6C shows the average (n>3) maximum decrease in mSpA BF reached during 1 min stimulation (symmetric biphasic pulse, PW 400 μs or 200 μs at 10 Hz) of the SpN plexus with different current amplitudes and two different PWs: 400 (filled circles) and 200 (filled squares) μs. Figure 6D shows the changes in mSpV BF (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 12 mA). Figure 6E shows the average (n=3) changes in sMABP and HR (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figures 6F and 6G summarize the mean (n=3) maximum changes in mSpA BF, sMABP, HR, and RR during 1 min of stimulation (symmetric biphasic pulses, PW400 μs at 10 Hz) of the SpN plexus (Figure 6F) or several dissected SpN bundles (Figure 6G) at different current amplitudes. Both graphs show the amplitude (measured peak to peak) of the recorded eCAP (expressed as % relative to the maximum response). The change in SpA BF is expressed as % as the maximum decrease from baseline, the change in HR is expressed as beats per minute (bpm), the change in sMABP is expressed as mmHg, and the change in RR is expressed as respiratory rates per minute (bpm). The two graphs also report the charge density per phase with respect to the stimulation amplitude used. [Figure 6G]Figure 6 shows the transient changes in mSpA BF, mSpV BF, sMABP and HR resulting from SpN stimulation, which are stimulus intensity dependent. Figure 6A shows the average (n=8) changes in mSpA BF (-30 to +180 seconds relative to the start of stimulation) during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figure 6B shows the maximum decrease in mSpA BF reached during 1 minute of stimulation (symmetric biphasic pulses, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes. Each line represents a tested animal. Figure 6C shows the average (n>3) maximum decrease in mSpA BF reached during 1 min stimulation (symmetric biphasic pulse, PW 400 μs or 200 μs at 10 Hz) of the SpN plexus with different current amplitudes and two different PWs: 400 (filled circles) and 200 (filled squares) μs. Figure 6D shows the changes in mSpV BF (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 12 mA). Figure 6E shows the average (n=3) changes in sMABP and HR (-30 to +180 sec relative to the start of stimulation) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at 10 Hz) of the SpN plexus with different current amplitudes (between 3.5 and 20 mA). Figures 6F and 6G summarize the mean (n=3) maximum changes in mSpA BF, sMABP, HR, and RR during 1 min of stimulation (symmetric biphasic pulses, PW400 μs at 10 Hz) of the SpN plexus (Figure 6F) or several dissected SpN bundles (Figure 6G) at different current amplitudes. Both graphs show the amplitude (measured peak to peak) of the recorded eCAP (expressed as % relative to the maximum response). The change in SpA BF is expressed as % as the maximum decrease from baseline, the change in HR is expressed as beats per minute (bpm), the change in sMABP is expressed as mmHg, and the change in RR is expressed as respiratory rates per minute (bpm). The two graphs also report the charge density per phase with respect to the stimulation amplitude used. [Figure 7A]Figure 7 shows that changes in mSpA BF, mSpV BF, sMABP, and HR during SpN stimulation were frequency dependent. Figure 7A shows the mean (n=3) changes in mSpA BF (-30 to +180 seconds relative to stimulation) during 1 minute stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). Figure 7B shows the mean (n=3) maximum decrease in mSpA BF observed during 1 minute stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). In Figures 7C-7D, graphs show changes in mSpV BF, sMABP, HR (expressed as % relative to pre-stimulation baseline) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). Data in Figure 7A are expressed as mean ± standard deviation (sd). In Figures 7A and 7C-7D, boxes indicate the time window of stimulation. [Figure 7B] Figure 7 shows that changes in mSpA BF, mSpV BF, sMABP, and HR during SpN stimulation were frequency dependent. Figure 7A shows the mean (n=3) changes in mSpA BF (-30 to +180 seconds relative to stimulation) during 1 minute stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). Figure 7B shows the mean (n=3) maximum decrease in mSpA BF observed during 1 minute stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). In Figures 7C-7D, graphs show changes in mSpV BF, sMABP, HR (expressed as % relative to pre-stimulation baseline) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). Data in Figure 7A are expressed as mean ± standard deviation (sd). In Figures 7A and 7C-7D, boxes indicate the time window of stimulation. [Figure 7C] Figure 7 shows that changes in mSpA BF, mSpV BF, sMABP, and HR during SpN stimulation were frequency dependent. Figure 7A shows the mean (n=3) changes in mSpA BF (-30 to +180 seconds relative to stimulation) during 1 minute stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). Figure 7B shows the mean (n=3) maximum decrease in mSpA BF observed during 1 minute stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). In Figures 7C-7D, graphs show changes in mSpV BF, sMABP, HR (expressed as % relative to pre-stimulation baseline) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). Data in Figure 7A are expressed as mean ± standard deviation (sd). In Figures 7A and 7C-7D, boxes indicate the time window of stimulation. [Figure 7D] Figure 7 shows that changes in mSpA BF, mSpV BF, sMABP, and HR during SpN stimulation were frequency dependent. Figure 7A shows the mean (n=3) changes in mSpA BF (-30 to +180 seconds relative to stimulation) during 1 minute stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). Figure 7B shows the mean (n=3) maximum decrease in mSpA BF observed during 1 minute stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). In Figures 7C-7D, graphs show changes in mSpV BF, sMABP, HR (expressed as % relative to pre-stimulation baseline) during 1 min stimulation (symmetric biphasic pulse, PW 400 μs at approximately 36.9 μC / cm2 / phase) of the SpN plexus at different frequencies (between 0.25 and 100 Hz). Data in Figure 7A are expressed as mean ± standard deviation (sd). In Figures 7A and 7C-7D, boxes indicate the time window of stimulation. [Figure 8] 8 shows the local and systemic effects of several dissected SpN fiber bundles at different frequencies. In particular, FIG. 8 shows representative experimental recordings of the local and systemic changes associated with stimulation of several SpN fiber bundles dissected away from an artery at different frequencies. HR data, sMABP data, stimulation input data, eCAP data, SpA BF raw data, and mSpA BF data from a representative experiment in the frequency range 3-300 Hz are shown. [Figure 9] SpA blood flow changes monitored via splenic ultrasonography during surgery. The images in Figure 9 were obtained from two different animals during SpN stimulation. Note the decreased Doppler tracing during stimulation (middle panel) versus before and after stimulation (top and bottom panels, respectively). [Figure 10A] FIG. 10 shows that SpN stimulation promoted survival. FIG. 10A is a Kaplan-Meier plot showing the difference in survival time to a given endpoint at 2 hours after in vivo LPS infusion. FIG. 10B is a box plot showing the lowest recorded mean arterial blood pressure (MABP; calculated as % of baseline) at 30 minutes after LPS infusion. A significant difference between the SpN-T and Sham groups is shown, P=0.0296. FIG. 10C and 10D are box plots showing the concentrations of TNFα (FIG. 10C) and IL-6 (FIG. 10D) at 0.5 hours after in vivo LPS infusion. A significant difference between the SpN-T and SpN-P groups is shown, P=0.0117. A significant difference between the SpN-T and Sham groups is also shown, P=0.0043. [Figure 10B]FIG. 10 shows that SpN stimulation promoted survival. FIG. 10A is a Kaplan-Meier plot showing the difference in survival time to a given endpoint at 2 hours after in vivo LPS infusion. FIG. 10B is a box plot showing the lowest recorded mean arterial blood pressure (MABP; calculated as % of baseline) at 30 minutes after LPS infusion. A significant difference between the SpN-T and Sham groups is shown, P=0.0296. FIG. 10C and 10D are box plots showing the concentrations of TNFα (FIG. 10C) and IL-6 (FIG. 10D) at 0.5 hours after in vivo LPS infusion. A significant difference between the SpN-T and SpN-P groups is shown, P=0.0117. A significant difference between the SpN-T and Sham groups is also shown, P=0.0043. [Figure 10C] FIG. 10 shows that SpN stimulation promoted survival. FIG. 10A is a Kaplan-Meier plot showing the difference in survival time to a given endpoint at 2 hours after in vivo LPS infusion. FIG. 10B is a box plot showing the lowest recorded mean arterial blood pressure (MABP; calculated as % of baseline) at 30 minutes after LPS infusion. A significant difference between the SpN-T and Sham groups is shown, P=0.0296. FIG. 10C and 10D are box plots showing the concentrations of TNFα (FIG. 10C) and IL-6 (FIG. 10D) at 0.5 hours after in vivo LPS infusion. A significant difference between the SpN-T and SpN-P groups is shown, P=0.0117. A significant difference between the SpN-T and Sham groups is also shown, P=0.0043. [Figure 10D]FIG. 10 shows that SpN stimulation promoted survival. FIG. 10A is a Kaplan-Meier plot showing the difference in survival time to a given endpoint at 2 hours after in vivo LPS infusion. FIG. 10B is a box plot showing the lowest recorded mean arterial blood pressure (MABP; calculated as % of baseline) at 30 minutes after LPS infusion. A significant difference between the SpN-T and Sham groups is shown, P=0.0296. FIG. 10C and 10D are box plots showing the concentrations of TNFα (FIG. 10C) and IL-6 (FIG. 10D) at 0.5 hours after in vivo LPS infusion. A significant difference between the SpN-T and SpN-P groups is shown, P=0.0117. A significant difference between the SpN-T and Sham groups is also shown, P=0.0043. [Figure 11A] FIG. 11 shows that SpN stimulation promoted survival similar to FIG. 10, but with additional data added. FIG. 11A is a Kaplan-Meier plot showing differences in survival time to a given endpoint at 2 hours after LPS injection. FIG. 11B is a box plot showing the lowest recorded mean arterial blood pressure (MABP; calculated as % of baseline) at 30 minutes after LPS injection. Significant differences between SpN2S and sham groups are shown. FIG. 11C and 11D are box plots showing the concentrations of TNFα (FIG. 11C) and IL-6 (FIG. 11D) at 0.5 hours after LPS injection. [Figure 11B] FIG. 11 shows that SpN stimulation promoted survival similar to FIG. 10, but with additional data added. FIG. 11A is a Kaplan-Meier plot showing differences in survival time to a given endpoint at 2 hours after LPS injection. FIG. 11B is a box plot showing the lowest recorded mean arterial blood pressure (MABP; calculated as % of baseline) at 30 minutes after LPS injection. Significant differences between SpN2S and sham groups are shown. FIG. 11C and 11D are box plots showing the concentrations of TNFα (FIG. 11C) and IL-6 (FIG. 11D) at 0.5 hours after LPS injection. [Figure 11C]FIG. 11 shows that SpN stimulation promoted survival similar to FIG. 10, but with additional data added. FIG. 11A is a Kaplan-Meier plot showing differences in survival time to a given endpoint at 2 hours after LPS injection. FIG. 11B is a box plot showing the lowest recorded mean arterial blood pressure (MABP; calculated as % of baseline) at 30 minutes after LPS injection. Significant differences between SpN2S and sham groups are shown. FIG. 11C and 11D are box plots showing the concentrations of TNFα (FIG. 11C) and IL-6 (FIG. 11D) at 0.5 hours after LPS injection. [Figure 11D] FIG. 11 shows that SpN stimulation promoted survival similar to FIG. 10, but with additional data added. FIG. 11A is a Kaplan-Meier plot showing differences in survival time to a given endpoint at 2 hours after LPS injection. FIG. 11B is a box plot showing the lowest recorded mean arterial blood pressure (MABP; calculated as % of baseline) at 30 minutes after LPS injection. Significant differences between SpN2S and sham groups are shown. FIG. 11C and 11D are box plots showing the concentrations of TNFα (FIG. 11C) and IL-6 (FIG. 11D) at 0.5 hours after LPS injection. [Figure 12A] FIG. 12 shows an anatomical analysis of the splenic artery from cadaver III. FIG. 12A shows the anatomical distance from the celiac trunk (origin SA) to the virtual sagittal plane, and the distance from the origin SA to the various branching pancreatic arteries (PA). Boxes indicate the location of the resected tissue. The length of the splenic artery loop is also shown. The location of the pancreas, spleen, and stomach in relation to the splenic artery is also shown. FIG. 12B shows the diameter of the splenic artery measured from each resected tissue sample. FIG. 12C shows an overview showing the spleen, pancreas, splenic artery (SA), and surrounding fat and connective tissue of cadaver IV. The SA presents three loops with a minimum height of 1.0 cm from the inner curve of the loop to the pancreas. The characteristics can be found in Table 5. [Figure 12B]FIG. 12 shows an anatomical analysis of the splenic artery from cadaver III. FIG. 12A shows the anatomical distance from the celiac trunk (origin SA) to the virtual sagittal plane, and the distance from the origin SA to the various branching pancreatic arteries (PA). Boxes indicate the location of the resected tissue. The length of the splenic artery loop is also shown. The location of the pancreas, spleen, and stomach in relation to the splenic artery is also shown. FIG. 12B shows the diameter of the splenic artery measured from each resected tissue sample. FIG. 12C shows an overview showing the spleen, pancreas, splenic artery (SA), and surrounding fat and connective tissue of cadaver IV. The SA presents three loops with a minimum height of 1.0 cm from the inner curve of the loop to the pancreas. The characteristics can be found in Table 5. [Figure 12C] FIG. 12 shows an anatomical analysis of the splenic artery from cadaver III. FIG. 12A shows the anatomical distance from the celiac trunk (origin SA) to the virtual sagittal plane, and the distance from the origin SA to the various branching pancreatic arteries (PA). Boxes indicate the location of the resected tissue. The length of the splenic artery loop is also shown. The location of the pancreas, spleen, and stomach in relation to the splenic artery is also shown. FIG. 12B shows the diameter of the splenic artery measured from each resected tissue sample. FIG. 12C shows an overview showing the spleen, pancreas, splenic artery (SA), and surrounding fat and connective tissue of cadaver IV. The SA presents three loops with a minimum height of 1.0 cm from the inner curve of the loop to the pancreas. The characteristics can be found in Table 5. [Figure 13A] Figure 13 shows that stimulation of the SpN induces a plateau in LPS-induced cardiovascular changes. (A and B) are representative traces of changes in MABP, dABP, sABP, HR, mCVP, ET CO2, and SpA mBF over time from baseline (mean 10 min prior to LPS injection) in sham (A) or splenic nerve stimulated (B) animals. LPS-induced changes in mCVP, HR, and ABP are smaller in stimulated animals. MABP = mean arterial blood pressure, dABP = diastolic arterial blood pressure, sABP = systolic arterial blood pressure, HR = heart rate, mCVP = mean central venous pressure, ET CO2 = end-tidal CO2, SpA mBF = splenic artery mean blood flow. [Figure 13B]Figure 13 shows that stimulation of the SpN induces a plateau in LPS-induced cardiovascular changes. (A and B) are representative traces of changes in MABP, dABP, sABP, HR, mCVP, ET CO2, and SpA mBF over time from baseline (mean 10 min prior to LPS injection) in sham (A) or splenic nerve stimulated (B) animals. LPS-induced changes in mCVP, HR, and ABP are smaller in stimulated animals. MABP = mean arterial blood pressure, dABP = diastolic arterial blood pressure, sABP = systolic arterial blood pressure, HR = heart rate, mCVP = mean central venous pressure, ET CO2 = end-tidal CO2, SpA mBF = splenic artery mean blood flow. [Figure 14A] FIG. 14 shows that stimulation of SpNs leads to a plateau in LPS-induced cardiovascular changes. (A) Stimulation reduces pulmonary vascular resistance compared to baseline (before LPS injection). Sham (unstimulated) animals receiving LPS injection have an increased PVS after LPS injection. (B) After LPS administration, stimulation increases SVR to a higher extent compared to sham animals. (C) After LPS injection, stimulation causes a stronger increase in PCWP compared to sham animals. PVS=pulmonary vascular resistance, SVR=systemic vascular resistance, PCWP=pulmonary capillary wedge pressure. [Figure 14B] FIG. 14 shows that stimulation of SpNs leads to a plateau in LPS-induced cardiovascular changes. (A) Stimulation reduces pulmonary vascular resistance compared to baseline (before LPS injection). Sham (unstimulated) animals receiving LPS injection have an increased PVS after LPS injection. (B) After LPS administration, stimulation increases SVR to a higher extent compared to sham animals. (C) After LPS injection, stimulation causes a stronger increase in PCWP compared to sham animals. PVS=pulmonary vascular resistance, SVR=systemic vascular resistance, PCWP=pulmonary capillary wedge pressure. [Figure 14C]FIG. 14 shows that stimulation of SpNs leads to a plateau in LPS-induced cardiovascular changes. (A) Stimulation reduces pulmonary vascular resistance compared to baseline (before LPS injection). Sham (unstimulated) animals receiving LPS injection have an increased PVS after LPS injection. (B) After LPS administration, stimulation increases SVR to a higher extent compared to sham animals. (C) After LPS injection, stimulation causes a stronger increase in PCWP compared to sham animals. PVS=pulmonary vascular resistance, SVR=systemic vascular resistance, PCWP=pulmonary capillary wedge pressure. [Figure 15] Figure 1 shows that stimulation of SpN suppresses the LPS-induced increase in systemic lipase compared to sham (unstimulated) animals. [Figure 16A]FIG. 16 shows that the human splenic nerve is a plexus of periaortic fascicles containing slow-conducting axons. FIG. 16 includes the following subsections: A) Splenic neurovascular bundle (NVB) of a human spleen containing sections of SpA, SpN, connective tissue, pancreas and lymph nodes freshly isolated from a donor. Two small cuff electrodes (650 μm diameter) are placed on selected small dissected fascicles. A schematic diagram has been created showing the location of the stimulation and recording cuffs (a and b). The dotted lines indicate the areas where the sections shown in B and C will be cut. (B) Section of human NVB stained with hematoxylin and eosin (H&E). The SpN fascicle is circled. (C) Section of stimulated fascicle isolated for electrophysiological studies. Section stained with H&E shows the nerve fascicle (circled) and fat / connective tissue. (D) eCAP recorded upon monopolar monophasic stimulation of a human SpN at 1 Hz and PW 400 μs before (upper panel) and after (lower panel) crushing the nerve between the stimulation and recording cuffs. The box on the left indicates the stimulation artifact, while the larger box on the right indicates the area where the eCAP should be observed, and the arrow indicates the eCAP. (E) Recruitment curve of a human SpN quantifying eCAP amplitude (expressed as % of maximum response) versus stimulation amplitude. Each point represents the mean amplitude of eight consecutive monopolar monophasic pulses delivered at 1 Hz and PW 400 μs. (F) Conduction velocity of all eCAP components recorded from human, porcine, and rat SpNs. (G) Strength-duration relationship (filled circles) of a human SpN obtained by stimulating dissected fascicles. Data represent the minimum current required to trigger a detectable eCAP at the different PWs examined. The graph also shows the corresponding charge densities (black triangles) for different stimuli (referred to as right Y-axis). Least squares regression curves are plotted for the intensity-duration and charge density data. (H) Charge densities required to stimulate three different species of SpNs at different PWs. Data were fitted with linear regression. Scale bars: B=2 mm, C=100 μm. [Figure 16B]FIG. 16 shows that the human splenic nerve is a plexus of periaortic fascicles containing slow-conducting axons. FIG. 16 includes the following subsections: A) Splenic neurovascular bundle (NVB) of a human spleen containing sections of SpA, SpN, connective tissue, pancreas and lymph nodes freshly isolated from a donor. Two small cuff electrodes (650 μm diameter) are placed on selected small dissected fascicles. A schematic diagram has been created showing the location of the stimulation and recording cuffs (a and b). The dotted lines indicate the areas where the sections shown in B and C will be cut. (B) Section of human NVB stained with hematoxylin and eosin (H&E). The SpN fascicle is circled. (C) Section of stimulated fascicle isolated for electrophysiological studies. Section stained with H&E shows the nerve fascicle (circled) and fat / connective tissue. (D) eCAP recorded upon monopolar monophasic stimulation of a human SpN at 1 Hz and PW 400 μs before (upper panel) and after (lower panel) crushing the nerve between the stimulation and recording cuffs. The box on the left indicates the stimulation artifact, while the larger box on the right indicates the area where the eCAP should be observed, and the arrow indicates the eCAP. (E) Recruitment curve of a human SpN quantifying eCAP amplitude (expressed as % of maximum response) versus stimulation amplitude. Each point represents the mean amplitude of eight consecutive monopolar monophasic pulses delivered at 1 Hz and PW 400 μs. (F) Conduction velocity of all eCAP components recorded from human, porcine, and rat SpNs. (G) Strength-duration relationship (filled circles) of a human SpN obtained by stimulating dissected fascicles. Data represent the minimum current required to trigger a detectable eCAP at the different PWs examined. The graph also shows the corresponding charge densities (black triangles) for different stimuli (referred to as right Y-axis). Least squares regression curves are plotted for the intensity-duration and charge density data. (H) Charge densities required to stimulate three different species of SpNs at different PWs. Data were fitted with linear regression. Scale bars: B=2 mm, C=100 μm. [Figure 16C]FIG. 16 shows that the human splenic nerve is a plexus of periaortic fascicles containing slow-conducting axons. FIG. 16 includes the following subsections: A) Splenic neurovascular bundle (NVB) of a human spleen containing sections of SpA, SpN, connective tissue, pancreas and lymph nodes freshly isolated from a donor. Two small cuff electrodes (650 μm diameter) are placed on selected small dissected fascicles. A schematic diagram has been created showing the location of the stimulation and recording cuffs (a and b). The dotted lines indicate the areas where the sections shown in B and C will be cut. (B) Section of human NVB stained with hematoxylin and eosin (H&E). The SpN fascicle is circled. (C) Section of stimulated fascicle isolated for electrophysiological studies. Section stained with H&E shows the nerve fascicle (circled) and fat / connective tissue. (D) eCAP recorded upon monopolar monophasic stimulation of a human SpN at 1 Hz and PW 400 μs before (upper panel) and after (lower panel) crushing the nerve between the stimulation and recording cuffs. The box on the left indicates the stimulation artifact, while the larger box on the right indicates the area where the eCAP should be observed, and the arrow indicates the eCAP. (E) Recruitment curve of a human SpN quantifying eCAP amplitude (expressed as % of maximum response) versus stimulation amplitude. Each point represents the mean amplitude of eight consecutive monopolar monophasic pulses delivered at 1 Hz and PW 400 μs. (F) Conduction velocity of all eCAP components recorded from human, porcine, and rat SpNs. (G) Strength-duration relationship (filled circles) of a human SpN obtained by stimulating dissected fascicles. Data represent the minimum current required to trigger a detectable eCAP at the different PWs examined. The graph also shows the corresponding charge densities (black triangles) for different stimuli (referred to as right Y-axis). Least squares regression curves are plotted for the intensity-duration and charge density data. (H) Charge densities required to stimulate three different species of SpNs at different PWs. Data were fitted with linear regression. Scale bars: B=2 mm, C=100 μm. [Figure 16D]FIG. 16 shows that the human splenic nerve is a plexus of periaortic fascicles containing slow-conducting axons. FIG. 16 includes the following subsections: A) Splenic neurovascular bundle (NVB) of a human spleen containing sections of SpA, SpN, connective tissue, pancreas and lymph nodes freshly isolated from a donor. Two small cuff electrodes (650 μm diameter) are placed on selected small dissected fascicles. A schematic diagram has been created showing the location of the stimulation and recording cuffs (a and b). The dotted lines indicate the areas where the sections shown in B and C will be cut. (B) Section of human NVB stained with hematoxylin and eosin (H&E). The SpN fascicle is circled. (C) Section of stimulated fascicle isolated for electrophysiological studies. Section stained with H&E shows the nerve fascicle (circled) and fat / connective tissue. (D) eCAP recorded upon monopolar monophasic stimulation of a human SpN at 1 Hz and PW 400 μs before (upper panel) and after (lower panel) crushing the nerve between the stimulation and recording cuffs. The box on the left indicates the stimulation artifact, while the larger box on the right indicates the area where the eCAP should be observed, and the arrow indicates the eCAP. (E) Recruitment curve of a human SpN quantifying eCAP amplitude (expressed as % of maximum response) versus stimulation amplitude. Each point represents the mean amplitude of eight consecutive monopolar monophasic pulses delivered at 1 Hz and PW 400 μs. (F) Conduction velocity of all eCAP components recorded from human, porcine, and rat SpNs. (G) Strength-duration relationship (filled circles) of a human SpN obtained by stimulating dissected fascicles. Data represent the minimum current required to trigger a detectable eCAP at the different PWs examined. The graph also shows the corresponding charge densities (black triangles) for different stimuli (referred to as right Y-axis). Least squares regression curves are plotted for the intensity-duration and charge density data. (H) Charge densities required to stimulate three different species of SpNs at different PWs. Data were fitted with linear regression. Scale bars: B=2 mm, C=100 μm. [Figure 16E]FIG. 16 shows that the human splenic nerve is a plexus of periaortic fascicles containing slow-conducting axons. FIG. 16 includes the following subsections: A) Splenic neurovascular bundle (NVB) of a human spleen containing sections of SpA, SpN, connective tissue, pancreas and lymph nodes freshly isolated from a donor. Two small cuff electrodes (650 μm diameter) are placed on selected small dissected fascicles. A schematic diagram has been created showing the location of the stimulation and recording cuffs (a and b). The dotted lines indicate the areas where the sections shown in B and C will be cut. (B) Section of human NVB stained with hematoxylin and eosin (H&E). The SpN fascicle is circled. (C) Section of stimulated fascicle isolated for electrophysiological studies. Section stained with H&E shows the nerve fascicle (circled) and fat / connective tissue. (D) eCAP recorded upon monopolar monophasic stimulation of a human SpN at 1 Hz and PW 400 μs before (upper panel) and after (lower panel) crushing the nerve between the stimulation and recording cuffs. The box on the left indicates the stimulation artifact, while the larger box on the right indicates the area where the eCAP should be observed, and the arrow indicates the eCAP. (E) Recruitment curve of a human SpN quantifying eCAP amplitude (expressed as % of maximum response) versus stimulation amplitude. Each point represents the mean amplitude of eight consecutive monopolar monophasic pulses delivered at 1 Hz and PW 400 μs. (F) Conduction velocity of all eCAP components recorded from human, porcine, and rat SpNs. (G) Strength-duration relationship (filled circles) of a human SpN obtained by stimulating dissected fascicles. Data represent the minimum current required to trigger a detectable eCAP at the different PWs examined. The graph also shows the corresponding charge densities (black triangles) for different stimuli (referred to as right Y-axis). Least squares regression curves are plotted for the intensity-duration and charge density data. (H) Charge densities required to stimulate three different species of SpNs at different PWs. Data were fitted with linear regression. Scale bars: B=2 mm, C=100 μm. [Figure 16F]FIG. 16 shows that the human splenic nerve is a plexus of periaortic fascicles containing slow-conducting axons. FIG. 16 includes the following subsections: A) Splenic neurovascular bundle (NVB) of a human spleen containing sections of SpA, SpN, connective tissue, pancreas and lymph nodes freshly isolated from a donor. Two small cuff electrodes (650 μm diameter) are placed on selected small dissected fascicles. A schematic diagram has been created showing the location of the stimulation and recording cuffs (a and b). The dotted lines indicate the areas where the sections shown in B and C will be cut. (B) Section of human NVB stained with hematoxylin and eosin (H&E). The SpN fascicle is circled. (C) Section of stimulated fascicle isolated for electrophysiological studies. Section stained with H&E shows the nerve fascicle (circled) and fat / connective tissue. (D) eCAP recorded upon monopolar monophasic stimulation of a human SpN at 1 Hz and PW 400 μs before (upper panel) and after (lower panel) crushing the nerve between the stimulation and recording cuffs. The box on the left indicates the stimulation artifact, while the larger box on the right indicates the area where the eCAP should be observed, and the arrow indicates the eCAP. (E) Recruitment curve of a human SpN quantifying eCAP amplitude (expressed as % of maximum response) versus stimulation amplitude. Each point represents the mean amplitude of eight consecutive monopolar monophasic pulses delivered at 1 Hz and PW 400 μs. (F) Conduction velocity of all eCAP components recorded from human, porcine, and rat SpNs. (G) Strength-duration relationship (filled circles) of a human SpN obtained by stimulating dissected fascicles. Data represent the minimum current required to trigger a detectable eCAP at the different PWs examined. The graph also shows the corresponding charge densities (black triangles) for different stimuli (referred to as right Y-axis). Least squares regression curves are plotted for the intensity-duration and charge density data. (H) Charge densities required to stimulate three different species of SpNs at different PWs. Data were fitted with linear regression. Scale bars: B=2 mm, C=100 μm. [Figure 16G]FIG. 16 shows that the human splenic nerve is a plexus of periaortic fascicles containing slow-conducting axons. FIG. 16 includes the following subsections: A) Splenic neurovascular bundle (NVB) of a human spleen containing sections of SpA, SpN, connective tissue, pancreas and lymph nodes freshly isolated from a donor. Two small cuff electrodes (650 μm diameter) are placed on selected small dissected fascicles. A schematic diagram has been created showing the location of the stimulation and recording cuffs (a and b). The dotted lines indicate the areas where the sections shown in B and C will be cut. (B) Section of human NVB stained with hematoxylin and eosin (H&E). The SpN fascicle is circled. (C) Section of stimulated fascicle isolated for electrophysiological studies. Section stained with H&E shows the nerve fascicle (circled) and fat / connective tissue. (D) eCAP recorded upon monopolar monophasic stimulation of a human SpN at 1 Hz and PW 400 μs before (upper panel) and after (lower panel) crushing the nerve between the stimulation and recording cuffs. The box on the left indicates the stimulation artifact, while the larger box on the right indicates the area where the eCAP should be observed, and the arrow indicates the eCAP. (E) Recruitment curve of a human SpN quantifying eCAP amplitude (expressed as % of maximum response) versus stimulation amplitude. Each point represents the mean amplitude of eight consecutive monopolar monophasic pulses delivered at 1 Hz and PW 400 μs. (F) Conduction velocity of all eCAP components recorded from human, porcine, and rat SpNs. (G) Strength-duration relationship (filled circles) of a human SpN obtained by stimulating dissected fascicles. Data represent the minimum current required to trigger a detectable eCAP at the different PWs examined. The graph also shows the corresponding charge densities (black triangles) for different stimuli (referred to as right Y-axis). Least squares regression curves are plotted for the intensity-duration and charge density data. (H) Charge densities required to stimulate three different species of SpNs at different PWs. Data were fitted with linear regression. Scale bars: B=2 mm, C=100 μm. [Figure 16H]FIG. 16 shows that the human splenic nerve is a plexus of periaortic fascicles containing slow-conducting axons. FIG. 16 includes the following subsections: A) Splenic neurovascular bundle (NVB) of a human spleen containing sections of SpA, SpN, connective tissue, pancreas and lymph nodes freshly isolated from a donor. Two small cuff electrodes (650 μm diameter) are placed on selected small dissected fascicles. A schematic diagram has been created showing the location of the stimulation and recording cuffs (a and b). The dotted lines indicate the areas where the sections shown in B and C will be cut. (B) Section of human NVB stained with hematoxylin and eosin (H&E). The SpN fascicle is circled. (C) Section of stimulated fascicle isolated for electrophysiological studies. Section stained with H&E shows the nerve fascicle (circled) and fat / connective tissue. (D) eCAP recorded upon monopolar monophasic stimulation of a human SpN at 1 Hz and PW 400 μs before (upper panel) and after (lower panel) crushing the nerve between the stimulation and recording cuffs. The box on the left indicates the stimulation artifact, while the larger box on the right indicates the area where the eCAP should be observed, and the arrow indicates the eCAP. (E) Recruitment curve of a human SpN quantifying eCAP amplitude (expressed as % of maximum response) versus stimulation amplitude. Each point represents the mean amplitude of eight consecutive monopolar monophasic pulses delivered at 1 Hz and PW 400 μs. (F) Conduction velocity of all eCAP components recorded from human, porcine, and rat SpNs. (G) Strength-duration relationship (filled circles) of a human SpN obtained by stimulating dissected fascicles. Data represent the minimum current required to trigger a detectable eCAP at the different PWs examined. The graph also shows the corresponding charge densities (black triangles) for different stimuli (referred to as right Y-axis). Least squares regression curves are plotted for the intensity-duration and charge density data. (H) Charge densities required to stimulate three different species of SpNs at different PWs. Data were fitted with linear regression. Scale bars: B=2 mm, C=100 μm. [Figure 17A]FIG. 17 shows A) an example human spleen sample with sutures showing the proximal end close to the abdominal cavity, (B) a schematic diagram of tissue slicing into blocks for histology, (C) a hematoxylin and eosin (H&E) stained slide from one of the blocks, and (D) the methodology for histomorphometric estimation. [Figure 17B] FIG. 17 shows A) an example human spleen sample with sutures showing the proximal end close to the abdominal cavity, (B) a schematic diagram of tissue slicing into blocks for histology, (C) a hematoxylin and eosin (H&E) stained slide from one of the blocks, and (D) the methodology for histomorphometric estimation. [Figure 17C] FIG. 17 shows A) an example human spleen sample with sutures showing the proximal end close to the abdominal cavity, (B) a schematic diagram of tissue slicing into blocks for histology, (C) a hematoxylin and eosin (H&E) stained slide from one of the blocks, and (D) the methodology for histomorphometric estimation. [Figure 17D] FIG. 17 shows A) an example human spleen sample with sutures showing the proximal end close to the abdominal cavity, (B) a schematic diagram of tissue slicing into blocks for histology, (C) a hematoxylin and eosin (H&E) stained slide from one of the blocks, and (D) the methodology for histomorphometric estimation. [Figure 18] FIG. 18 shows (left) fascicle diameter, (center) fascicles extending into the adventitia (outer splenic artery wall) at proximal, middle, and distal sites of the splenic neurovascular bundle (NVB), and (right) percentage of fascicles relative to distance from the adventitia. [Figure 19A] FIG. 19 shows in vivo data from porcine splenic neurovascular bundle stimulation: (A) population recruitment curves and (B) strength-duration curves. [Figure 19B] FIG. 19 shows in vivo data from porcine splenic neurovascular bundle stimulation: (A) population recruitment curves and (B) strength-duration curves. [Figure 20A]FIG. 20: (A) Recruitment curves from in silico modeling in pigs where the x-axis represents charge injection estimates at 400us pulses; (B) the same recovery curves where the x-axis reflects stimulation amplitude; (C) Recruitment curves from in silico modeling in humans where the x-axis represents charge injection estimates at 400us (blue) and 1ms pulses (red); (D) the same recovery curves where the x-axis reflects stimulation amplitude (mA). [Figure 20B] FIG. 20: (A) Recruitment curves from in silico modeling in pigs where the x-axis represents charge injection estimates at 400us pulses; (B) the same recovery curves where the x-axis reflects stimulation amplitude; (C) Recruitment curves from in silico modeling in humans where the x-axis represents charge injection estimates at 400us (blue) and 1ms pulses (red); (D) the same recovery curves where the x-axis reflects stimulation amplitude (mA). [Figure 20C] FIG. 20: (A) Recruitment curves from in silico modeling in pigs where the x-axis represents charge injection estimates at 400us pulses; (B) the same recovery curves where the x-axis reflects stimulation amplitude; (C) Recruitment curves from in silico modeling in humans where the x-axis represents charge injection estimates at 400us (blue) and 1ms pulses (red); (D) the same recovery curves where the x-axis reflects stimulation amplitude (mA). [Figure 20D] FIG. 20: (A) Recruitment curves from in silico modeling in pigs where the x-axis represents charge injection estimates at 400us pulses; (B) the same recovery curves where the x-axis reflects stimulation amplitude; (C) Recruitment curves from in silico modeling in humans where the x-axis represents charge injection estimates at 400us (blue) and 1ms pulses (red); (D) the same recovery curves where the x-axis reflects stimulation amplitude (mA). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0163] Study 1A: Characterization of the splenic artery nerve Materials and Methods A gross anatomical examination of the spleen together with associated organs was performed on 12 female pig cadavers (body size 22-120 kg) within 1 hour of euthanasia. The following measurements were made; splenic length and width, length of the celiac artery (from the aorta to its bifurcation into the left gastric artery and splenic artery), length of the splenic artery (SpA) (from the bifurcation of the celiac artery to its entry into the parenchyma of the spleen), diameter of the SpA measured at the splenic hilum 1 cm distal to the celiac artery, distance from the pancreas to the splenic lymph nodes, and distance from the pancreas to the splenic lymph nodes. Also recorded were the number and course of abdominal vagus nerve branches, celiac ganglion, splanchnic nerves, and splenic nerve. The SpA associated with the splenic nerve was processed for hematoxylin and eosin (H&E) histology.
[0164] Spleens with intact vasculature and innervation were harvested from 12 female pig cadavers (body weight 22 kg, n=6; body weight 45 kg, n=6). All tissues were harvested within 1 hour of euthanasia and immediately fixed in 10% neutral buffered formalin. The SpA with intact perivascular neuronal networks was sectioned every 5 mm from the origin of the celiac trunk branch to the splenic hilum. This resulted in five sections, defined as the branch, proximal SpA, mid SpA, distal SpA, and hilum location. The proximal SpA section corresponds to the location of cuff placement in the following electrical stimulation studies described below.
[0165] At each of these five locations, sections were processed for routine H&E staining. Proximal, mid, and distal SpA sections were processed for immunohistochemical staining and semi-ultrathin sectioning and staining with osmium tetroxide and toluidine blue.
[0166] Digital images of H&E stained sections were obtained at 2x magnification and appropriate software (Image J 1.50i) was used for histomorphometric analysis as described in detail below. After manual selection of all individual nerve bundles using the ROI manager function, the number of nerve bundles around the artery was counted and the fiber bundle size was assessed by measuring the minimum Feret's diameter (μm).
[0167] Total nerve area (μm 2The distribution of fascicles around the artery was quantified by assessing the percentage of the arterial circumference in which fascicles were identified, with a 360° distribution defined as 100%. The distance from each fascicle to the outer arterial wall was measured by drawing the shortest possible vertical line from each fascicle to the arterial wall. The splenic artery external and internal diameters were measured at the proximal, mid, and distal SpA locations.
[0168] Double staining for tyrosine hydroxylase (TH) and acetylcholine transferase (ChAT) was used to assess neuronal phenotype. By counterstaining with neurofilament 200 (NF200) and the nuclear stain 4',6-diamidino-2-phenylindole (DAPI), NF200-TH double positive nerves were considered sympathetic, whereas NF200-ChAT double positive nerves were considered parasympathetic. To determine the proportion of efferent versus afferent nerves, the same locations were double stained with the efferent marker TH and the afferent marker calcitonin gene-related peptide (GCRP). Two different digital images were randomly captured from each nerve at 20x magnification, and pseudocolor composites were generated using the appropriate software (AxioVision LE64).
[0169] Myelination of SpN axons was assessed by immunofluorescence staining in addition to semi-thin sections. Different regions of SpA and SpN were stained with antibodies against neurofilament and β-III tubulin and myelin basic protein (MBP). Pseudocolor composite images were generated using appropriate software as described above. Semi-thin sections were stained with osmium and toluidine blue. Digital images were acquired at 100x magnification and the numbers of myelinated and unmyelinated axons were manually counted within an area of 100x100 μm. This procedure was repeated three times per nerve and the average of these was used for further analysis. This procedure was also used to determine axon density (number of axons / mm 2 ) was used to derive
[0170] All statistical analyses were performed using commercial statistical software (JMP Pro 13.0.0). Due to non-normal distributions, all histomorphometric measurements were compared between different pig sizes and SpA locations using the Wilcoxon rank sum test. Statistical significance was defined as P < 0.05.
[0171] result Neurovascular structures enter and exit the spleen only along the visceral aspect. Specifically, the first major abdominal branch of the aorta, the celiac artery, divides into the hepatic artery, SpA, and LGA (Figure 3). The SpA enters the spleen at a hilum located a few centimeters distal to the splenic base. At the hilum, the SpA immediately bifurcates into one dorsal branch that courses toward the splenic base and one ventral branch that runs along the visceral aspect toward the splenic superior pole. The left gastroepiploic artery arises from this ventral SpA branch near the transition between the middle and distal third of the spleen.
[0172] At the base of the spleen, the dorsal SpA branch splits into several smaller arteries identified as the short gastric arteries that course towards the greater curvature of the stomach. These arteries are considered terminal branches of the SpA, but they can provide a collateral blood supply to the spleen by anastomosis with branches of the LGA and left gastroepiploic artery. The splenic vein (SpV) runs parallel to the SpA along the visceral aspect of the spleen from the apex to the hilum. After leaving the splenic hilum, the SpV courses in close contact with the SpA for a short distance before course medially and drains into the hepatic portal vein, which then drains into the posterior vena cava. This leaves a narrow space where the artery and vein extend apart for a few millimeters in the soft tissue. This region, just distal to the bifurcation of the SpA and the celiac trunk into the LGA, has been identified as the optimal interface point for the following functional studies. At this location, the diameter of the SpA is 1.5-3 mm in 30 kg animals, 2-4 mm in 60 kg animals, and 5-8 mm in 110 kg animals.
[0173] The SpNs are composed of a plexus of fibers that run along the SpA toward the splenic hilum. The origin of these nerves is difficult to determine, although fibers can be seen to arise from the CG, located just caudal to the branching of the celiac artery to the SpA and LGA. Data from previous studies, mainly performed in rodents, determined that many SpNs originate from the celiac and adrenal ganglia. This has yet to be demonstrated in larger animal species.
[0174] In rodents, other nerves have been described to innervate the spleen in addition to the periaortic SpNs. More specifically, an apical nerve has been described in the gastrosplenic ligament of rats and mice. This is a sympathetic nerve (TH+) that may originate from the paravertebral sympathetic nerve and extends to the apex of the spleen in the gastrosplenic ligament.
[0175] All histological measurements are presented in Table 1. The SpN to SpA distance was the only measurement in which the 45 kg pigs were significantly greater than the 22 kg pigs (P < 0.001 at mid-SpA and distal SpA locations). Therefore, for all other measurements, data from all pigs were combined for statistical analysis. There was a decrease in the number of periarterial nerve bundles along the SpA from proximal to distal. There were statistically significantly more fascicles at the branching points than at all other locations (P < 0.0001). At the splenic hilus, nerve bundles were significantly more numerous than at other locations (P < 0.0001). The SpA external diameter was significantly greater at the proximal SpA than at the mid- and distal SpA locations (P = 0.0162 and P = 0.0158, respectively). The SpN / SpA distance also decreased from proximal to distal. In 45 kg pigs, the distance was significantly greater at the bifurcation than at all other locations (P<0.001), and in 45 kg pigs, the SpN / SpA distance was significantly greater at the hilus than at the proximal, middle, and distal SpA locations (P<0.008).
[0176] Circumferential SpN distribution was significantly higher at proximal than at mid and distal SpA locations (P = 0.02 and P = 0.15, respectively), and fiber bundles were more evenly distributed circumferentially around the SpA at proximal locations, whereas at mid and distal SpA the distribution pattern was more bimodal with fiber bundles clustered on opposite sides of the artery.
[0177] In pigs, nerves are found along both the short gastric and gastroepiploic arteries in the gastrosplenic ligament (Figure 4). These nerves appear to be a continuation of the major periaortic SpN plexus, running towards (and away from) the stomach. At this location, immunohistochemical analysis was performed and SpNs at every location were found to be TH+ and ChAT-. Interestingly, along the major SpA, nerve fibers positive for calcitonin gene-related peptide (CGRP), commonly used as a marker for afferent neurons, were identified.
[0178] The number of nerve bundles and fascicle size observed in these two regions are very small compared to that observed along the main SpA. Quantification of the number and relative diameter of nerve bundles along the main SpA and along different anatomical locations in 45-50 kg domestic pigs is shown in Figures 4E and 4F.
[0179] [Table 1]
[0180] Further histochemical and immunohistochemical analyses showed that the SpNs were composed of >99.9% unmyelinated fibers. Toluidine blue staining of semi-ultrathin sections did not, in fact, reveal any myelinated axons. In agreement with this, staining for myelin basic protein (MBP) revealed a negligible number of positive axons (<0.01%). Both techniques to assess myelination revealed an almost complete lack of myelin in the studied sections of the SpNs, as shown in Figure 5.
[0181] Consideration The histological analysis performed here showed that the SpNs constitute a neurovascular plexus along the main SpA in addition to the short gastric and gastroepiploic arteries. The number of fascicles is unexpectedly high. Considering the average size of the SpN axons (diameter about 2 μm), it can be calculated that the SpN plexus would contain (at most) a total of about 150,000 axons at the level of the main SpA (mid-section). Some of these axons innervate the SpA endothelium, and some of these axons instead enter the spleen and form synaptic connections with either smooth muscle or immune cells at the level of the marginal zone between the white and red pulp, as well as within the white pulp, as previously described in other species [8, 9, 10, 11, 12]. The number of axons is expected to be high, considering that the human vagus nerve (which has the same size as the porcine vagus nerve), which targets numerous organs in the body, is estimated to contain about 100,000 axons. The high number of axons in the SpNs may be related to the size of the spleen in pigs, which has a volume approximately 2-3 times larger than the human spleen, and the length of the arteries that the SpNs presumably innervate. The number of fiber bundles and axons in human SpNs may vary.
[0182] The spleen of pigs (and other mammals, such as dogs) also appears to contain a higher proportion of smooth muscle cells than the human spleen.
[13] However, there is evidence that the human spleen is capable of contracting during stressful situations, such as apnea and physical exercise.[14,15]
[0183] The vascular organization of the splenic artery and vein is slightly different in pigs and humans. In pigs, the SpA and SpV run toward and proximally from the spleen. Furthermore, the SpV and SpA do not exhibit the loops or turns that can be observed in humans. Therefore, only a short (approximately 1-1.5 cm) segment of the SpA near the trifurcation point of the celiac trunk should be separated (away) from the SpV. This segment of the artery was selected as the best intervention point in the stimulation test described below. Access to the neurovascular bundle at this location is indeed safer, thus reducing the chance of damaging the nerves in addition to the artery and vein during dissection.
[0184] Study 1B: Characterization of the splenic artery loop Materials and Methods To investigate the different nerve pathways to the spleen, six formaldehyde-preserved human cadavers were studied. Tissue blocks of the spleen, stomach, pancreas, omentum, gastrosplenic ligament, and, where present, the phrenic splenic ligament were removed.
[0185] A number of plexus-related characteristics were analyzed, including dissection parameters of the overall splenic artery (e.g., length, cross-sectional diameter, etc.), splenic artery loops, and splenic artery branches, in addition to parameters related to the relationship of the splenic artery to the surrounding tissues.
[0186] Splenic artery tissue samples were also analyzed by immunohistochemical staining (IHC). IHC was used to detect and quantify associated nerve tissue. Overall, sympathetic and afferent nerve tissue was detected immunohistochemically in tissue sections using anti-protein gene product 9.5 (PGP9.5), anti-tyrosine hydroxylase (TH), and anti-calcitonin gene-related peptide (CGRP) antibodies, respectively. Immunohistochemical staining and visualization were performed routinely. For all splenic plexus samples, automatically stitched overview images (tile scans) were generated from composite brightfield and fluorescent microscopy images and subjected to further image analysis using FIJI Image J (with additional plug-ins).
[0187] result In all cases, the splenic artery originated from the celiac trunk. Its course was generally suprapancreatic, although in some cadavers parts of the splenic artery were retropancreatic, intrapancreatic, or prepancreatic.
[0188] The mean absolute length of the splenic artery (measured by placing a cord along it) was 18.02 cm, with a mean linear distance of 11.67 cm from the origin of the celiac trunk to the virtual sagittal plane of the spleen. The virtual sagittal plane represents a line connecting the upper and lower poles of the spleen. The mean diameter of the splenic artery at its origin was 0.52 cm. The mean diameter of the splenic artery was 0.40 cm before its terminal branches. The mean number of terminal branches was 5.5 (range 2-9), and the mean diameter of the terminal branches was 0.22 cm (range 0.05-0.5). Table 2 shows the splenic artery parameters for each cadaver analyzed, in addition to the mean values for each parameter.
[0189] Figure 11 shows an overview of the splenic artery of cadaver III and its branches. The distance from each branch to the origin of the SA and to the virtual sagittal plane of the spleen is shown. In addition to this, the position and dimensions of the loops can be seen. The boxes indicate the location of the samples taken for microscopy. In Figure 11, the diameters of certain points along the splenic artery and its branches are shown.
[0190] [Table 2]
[0191] Figure 11 shows an overview of the splenic artery of cadaver III and its branches. The distance from each branch to the origin of the SA and to the virtual sagittal plane of the spleen is shown. In addition to this, the position and dimensions of the loops can be seen. The boxes indicate the location of the samples removed for microscopy. In Figure 11, the diameters of certain points along the splenic artery and its branches are shown.
[0192] Splenic artery loop In the context of the present example, a splenic artery loop was defined as a segment of the splenic artery separated from the surface of the pancreas by a distance of at least 1.0 cm, the distance being calculated from the inner curvature of the splenic artery to the surface of the pancreas.
[0193] The average number of "loops" observed across the analyzed sample pool was 1.34. One cadaver had no loops, three cadavers had one loop, one cadaver had two loops, and one cadaver had three loops. The average loop neck (distance between the inner curved surface of both legs of the loop) was 1.99 cm. The average distance from the outside of the first leg of the loop to the origin of the splenic artery was 6.48 cm. The average distance from the outside of the second leg of the loop to the virtual sagittal plane of the spleen was 4.34 cm. There was a large variability in both of these distances. The average loop height (distance between the inner curved surface of the top of the loop and the surface of the pancreas) was 1.29 cm. The average diameter of the splenic artery preceding the first leg of the loop and following the second leg of the loop were 0.46 cm and 0.41 cm, respectively. Individual and average splenic artery loop parameters for each cadaver are shown in Table 3.
[0194] [Table 3]
[0195] Immunohistochemical staining The results of immunohistochemical analysis of nerve bundles surrounding the splenic artery loop are shown in Table 4. The average number of nerve bundles surrounding the splenic artery loop was 25. The average diameter of the nerve bundles was 119 μm. The average total area of sympathetic (TH-IR) nerve tissue was 196,986 μm. 2 The mean diameter of the neurovascular bundle (splenic artery and surrounding tissue) was 8553 μm (5177-12447). The mean distance of the nerve bundle to the location of the cuff (outer layer of tissue) was 628 μm (32-2678).
[0196] [Table 4]
[0197] Overall, total PGP-IR (general nerve tissue) and TH-IR (sympathetic nerve tissue) staining was comparable in the nerve bundles surrounding the splenic artery loop. There was minimal staining of CGRP-IR (afferent nerve tissue). Samples of total areas of PGP-IR, TH-IR, and CGRP-IR nerve tissue calculated for three samples obtained from separate cadavers are shown in Table 5.
[0198] [Table 5]
[0199] Consideration The analysis performed herein indicates that splenic artery loops are a commonly observed feature of the splenic artery. The loops are typically characterized by a separation distance from the surface of the spleen to the inner curvature of the splenic artery of approximately 1 cm. This separation distance makes these sites favorable targets for surgical implantation of a neural stimulation system for neuromodulation of the splenic artery nerve. Splenic artery loops are more accessible and, by eliminating the need to dissect the splenic artery from the surface of the pancreas, there are fewer risks associated with trauma caused by the procedure.
[0200] Test 2: Electrical stimulation of the splenic artery nerve Materials and Methods A total of eight pigs (body weight 40-50 kg) were used for the histological and electrophysiological characterization of the splenic nerve.
[0201] On the day of the experiment, animals were sedated with ketamine (1.5 mg / kg) and midazolam (0.5 mg / kg) administered intramuscularly. An intravenous catheter was placed into one auricular vein and anesthesia was induced with intravenous administration of propofol (2 mg / Kg). An endotracheal tube was placed and anesthesia was maintained with inhaled sevoflurane in conjunction with a constant constant infusion (CRI) of fentanyl (0.2 μg / Kg / min).
[0202] After induction of general anesthesia, animals were positioned in supine position for placement of bilateral indwelling jugular venous catheters and one femoral artery catheter under ultrasound echo guidance. Animals receiving implantation of the SpN cuff were subsequently repositioned in right lateral decubitus position.
[0203] The surgical approach for SpN cuff implantation was as follows: The thoracic-lumbar junction was supported and slightly elevated using sandbags. After appropriate surgical preparation (clipping and sterile scrubbing with chlorhexidine gluconate and alcohol), the left flank was aseptically draped exposing an area of 20x25cm centered on the penultimate rib. A 15cm skin incision was made in the penultimate intercostal space using monopolar electrocautery. The cut was continued through the subcutaneous tissue and intercostal muscles until the peritoneum was exposed. Two finochet retractors were placed retroperitoneally, taking care to engage the ribs. Over the next few minutes, the retractors were gradually widened, exposing the left flank measuring approximately 10x8cm. The retractor blades were covered with gauze sponges soaked in carboxymethylcellulose (CMC). The peritoneum was incised longitudinally and sutured (Vicryl 2-0; Ford interlocking suture pattern) to the skin overlying the opener blades to minimize the risk of tearing the spleen during the procedure. By careful digital manipulation, the spleen was exteriorized and the splenic artery (SpA) was identified along its visceral aspect. A short segment of the SpA was carefully dissected free of surrounding soft tissue for placement of a 1-mm ultrasound flow probe (Transonic) in the mid-spleen, proximal to where it bifurcates into the left gastroepiploic artery. After probe placement, the spleen was repositioned into the abdomen.
[0204] The gastrosplenic ligament at the hilum of the spleen was incised using Metzenbaum scissors, exposing the SpA, by slightly rotating the splenic visceral base towards the operator and gently retracting ventrally on the spleen. The artery was followed in a dorsal direction to its origin (i.e., the bifurcation of the left gastric artery (LGA) and the celiac artery to the SpA). Just distal to this bifurcation, a ∼1 cm segment of the SpA with an intact periarterial SpN network was circumferentially isolated by blunt dissection using Metzenbaum scissors. A curved Mixter artery forceps was inserted caudally to cranially under the artery, while grasping a piece of a 2.5 mm diameter CorTec cuff introduced into the surgical field using straight microdissection forceps. The cuff was placed around the SpA and the intact periarterial SpN network by reversing the movement of the Mixter forceps, taking care that the two pieces of the cuff were apposed when correctly placed. Splenic and arterial tension was subsequently released, SpA and SpV (splenic vein) blood flow measurements were examined, and finally the rib retractor was partially closed and the exposed incision was covered with saline-soaked gauze sponges.
[0205] Electrophysiological experiments were also performed. These typically involved dissecting and cuffing (using 500 μm diameter bipolar or tripolar CorTec cuffs) one or several separate SpN fascicles a few centimeters distal (closer to the spleen) to the stimulation cuff to allow recording of evoked compound action potentials (eCAPs) during stimulation of the entire SpN plexus or a few fascicles (see Figure 5). Different combinations of blockade of nerve signals either upstream or downstream of the stimulation site (e.g., by local administration of local anesthesia or transection of SpN fascicles) were also performed.
[0206] Recorded eCAPs were amplified and filtered (100-1000 Hz) using a Model 1800 2-channel microelectrode AC amplifier (A-M Systems). Neural activity was continuously monitored using an oscilloscope and recorded on a computer using a 16-channel PowerLab (AD Instruments) acquisition system and LabChart8 software with a sampling rate of 20 kHz. eCAPs were generally averaged (8 pulses) and the peak-to-peak or area under the curve (AUC) of the averaged response was quantified. The conduction velocity of the eCAP component in the SpNs was calculated from the distance between the stimulation and recording sites and the latency of the eCAP signal.
[0207] Electrocardiogram (ECG), heart rate (HR), arterial blood pressure, respiratory rate (RR), pulse oximetry, capnography, and spirometry were monitored throughout the procedure. Temperature was recorded continuously via an intranasal probe. Arterial blood gases were analyzed and pH, glucose, pO2 and pCO2, and K+ levels were monitored throughout the experiment. All physiological parameters were recorded on a record sheet (every 5-10 min) in addition to the level of sevoflurane used. Physiological data were also digitized using a Powerlab acquisition system and LabChart software. All parameters were generally sampled at frequencies between 0.1 and 2 kHz.
[0208] Depth of anesthesia was assessed by eyelid reflex, corneal reflex, midventral eye position, and jaw tone.
[0209] Furthermore, physiological parameters were used in addition to the bispectral index monitoring system (levels between 30 and 60) to adjust the anesthesia level. In some cases, bolus administration of propofol was also used.
[0210] In some cases, intraoperative ultrasound of the spleen was used for real-time monitoring of SpA blood flow changes during SpN stimulation.For this procedure, an intraoperative probe (i12L-RS linear intraoperative transducer 4-10 MHz, footprint 29x10 mm, field of view 25 mm; GE Vivid-i) was used.
[0211] SpA blood flow changes were assessed by color Doppler and continuous wave spectral tracking. After color Doppler identification of SpA within the splenic parenchyma 2-3 cm distal to the splenic hilum, continuous wave spectral tracking of SpA flow was obtained by directing the window cursor to the center of the SpA lumen. After acquisition of a representative signal, the sonography probe and cursor window were left in position while SpN stimulation began.
[0212] All statistical analyses were performed with commercially available statistical software (JMP Pro 13.0.0 or GraphPad Prism 5.0).
[0213] result Recordings of eCAPs generated during SpN stimulation, either stimulating the entire SpN plexus with a periarterial cuff or a few fascicles with a smaller cuff, generated eCAPs with a specific latency dependence on the distance between the stimulation and recording sites (Figure 5B). The range of conduction velocities of the different components of the eCAP is shown in Figure 5C. Stimulation of either the entire plexus or a few fascicles generated eCAPs with a mean velocity below 1 m / s (Figure 5C). This conduction velocity is consistent with the histological results in the characterization data below, which explain that the SpN is an unmyelinated nerve. The relationship between current amplitude and pulse duration required to elicit eCAPs stimulating either the entire plexus or a few fascicles is shown in Figures 5D and 5E (respectively). When stimulating the entire plexus with a periarterial cuff, the threshold for the nerve response was 7.692 to 15.58 μC / cm. 2 When stimulating several dissected fiber bundles with smaller cuffs, thresholds ranged from 5.796 to 11.594 μC / cm 2In both cases, the threshold current density for eCAP recordings was lower at short pulse widths (PW).
[0214] SpN biphasic stimulation for 1 min at 10 Hz and PW 400 μs above a certain current threshold consistently induced a transient blood flow reduction in the distal SpA as measured via a perivascular flow probe. There was a clear dose-response relationship between delivered current and flow reduction. The higher the amplitude, the stronger the observed reduction in blood flow (Figure 6A). Blood flow change thresholds, defined as a 5% change in mean SpA blood flow (mSpA BF) compared to pre-stimulation baseline, were observed at around 4.5 mA (at PW 400 μs) and 12 mA (at pulse width 200 μs) (Figures 6B and 6C). Calculations of threshold phase-wise charge densities to induce blood flow changes were very similar, around 13.8 μC / cm at 400 μs. 2 / phase, 18.46μC / cm at 200μs 2 / phase. 12mA and PW400μs (36.9μC / cm 2 Stimulation at 100-fold (p<0.01) induced a mean maximum BF decrease of approximately 40% from baseline values in SpA.
[0215] In parallel, blood flow recordings in the SpV were recorded using a Doppler flow probe placed at the base of the spleen where the vein leaves the splenic hilum. Interestingly, stimulation (symmetric biphasic pulses, 400, 10 Hz for 1 min) evoked an increase in mean SpV blood flow (mSpV BF) that was current amplitude dependent. At 12 mA and PW 400 μs (36.9 μC / cm 2Stimulation at 100 Hz / phase (100 / phase) induced a maximum increase of approximately 200% when compared to baseline mSpV BF. The transient decrease in mSpA BF was also accompanied by a transient increase in systemic mean arterial blood pressure (sMABP). This increase from baseline (average 1-6 mmHg) was again correlated with stimulation intensity (Figure 6E). A consistent change in sMABP was observed with stimulation, eliciting a 20-30% decrease in SpA flow. In contrast, HR was only minimally affected (<3 bpm change, either increase or decrease) but was more consistent only at high stimulation amplitudes (>45 μC / cm 2 / phase evoked changes of 3 to 10 bpm) (Figure 12G). SpN stimulation did not affect respiratory rate (RR) under the conditions tested.
[0216] Different current amplitudes (1 to 50 mA, 3.076 to 153.8 μC / cm 2 The changes observed in mSpA BF, sMABP, HR, and RR during 1 min of stimulation (symmetric biphasic pulses, 10 Hz, PW 400 μs) with 100 Hz (corresponding to 100 / phase) are summarized in FIG. 6F. In FIG. 6F it can be seen how the magnitude of these changes correlated with the recordings of eCAP (black lines and circles) from the SpNs. The higher the number of recruited fibers (measured as % eCAP relative to the maximum recorded response), the stronger the decrease in mSpA BF and other associated changes.
[0217] Direct stimulation of individual SpN bundles dissected away from the SpA (using a 500 μm diameter cuff at position "b" in Figure 4A) induced similar changes in mSpA BF, sMABP, and HR. 2 These changes occurring during stimulation (corresponding to 100 μC / cm 2 / phase) are summarized in Figure 12G. Even in this case, the associated changes depended on the proportion of fibers recruited by the stimulation (eCAP, shown in black). The maximum eCAP (and therefore the maximum change) was approximately 153 μC / cm 2 when the entire plexus was stimulated. 2 / phase, and about 70 μC / cm 2The magnitude of changes obtained when stimulating a few fiber bundles was lower than that obtained when stimulating the entire plexus, as expected, because the total number of fibers stimulated was lower and the frequency was lower.
[0218] Blood flow changes in mSpA were also affected by different frequencies of stimulation. Stimulation at different frequencies (between 0.25 and 100 Hz) (symmetric biphasic pulse, PW 400 μs, approximately 36.9 μC / cm 2 When stimulation was performed at 30-50 Hz (1 min per phase), 30-50 Hz reliably induced the strongest blood flow reduction in SpA (Figure 7A). Above 50 Hz (between 70-100 Hz), the reduction in BF was actually smaller and in the range of the reduction obtained with 10 Hz stimulation (Figure 7B). It was also found that the changes in mSpV BF, sMABP, and HR depended on the frequency of stimulation applied. The strongest effects were again observed between 30-50 Hz (Figures 7C-7D).
[0219] This was achieved by maximally injecting only a small bundle of fibers dissected away from the artery (70 μC / cm 2 This was again observed when stimulating the brain at frequencies of 30 to 50 Hz (Fig. 7D). A stronger decrease in mSpA BF occurred already at lower frequencies (<1 Hz) due to the recruitment of more nerve fibers compared to the stimulation amplitudes used for the whole plexus during frequency analysis. Consistently, however, the maximal decrease was observed between 30 and 50 Hz (Fig. 7D).
[0220] To further confirm that the observed changes in SpA BF were due to direct neuronal activation (rather than smooth muscle stimulation), lidocaine (2% lidocaine hydrochloride solution) was applied locally around the implanted SpN cuffs (either periarterial cuffs or dissected fascicle cuffs). Lidocaine is a specific blocker of fast voltage-dependent Na+ channels. Lidocaine was able to block the changes in SpA BF. Furthermore, mechanical occlusion of the SpA was able to reduce BF by 80% and did not cause any changes in sMABP or HR. In addition, transection of the central end of the SpN (proximal to the cuff) did not abolish the stimulation effects on SpA blood flow, sMABP, and HR. Also, transection of the SpNs within the GEP and SG segments did not prevent these changes. Interestingly, all these effects were abolished only when the peripheral end of the SpN (distal to the cuff) was cut. All these data suggest that the changes in SpA BF and SpV BF are neuronally driven and related to contraction of the SpA as well as the splenic capsule, whereas the changes in sMABP and HR are probably due to increased outflow of blood from the spleen to the heart rather than to activity of neuronal pathways to the brain.
[0221] In some animals, SpA blood flow changes during stimulation were also monitored using intraoperative ultrasound at the splenic hilum. After identifying the SpA by color Doppler, changes in BF were monitored as the Doppler signal as shown in Figure 8. During stimulation at 10 Hz, a decrease in BF was readily observable as indicated by the altered amplitude and shape of the flow trace.
[0222] Consideration Splenic nerve stimulation was accompanied by transient local changes in mSpA BF and mSpV BF in addition to splenic contraction. These changes were due to direct activation of SpNs rather than direct stimulation of the smooth muscle of the SpA. Splenic contraction during SpN stimulation has been previously reported in other species
[16] . The observed changes in mSpA BF were highly consistent between animals. The variability was probably mainly due to different fitting of the cuff around the SpN plexus in different animals. The changes in SpA BF could be easily monitored via noninvasive ultrasound and therefore could also be used as a marker to evaluate effective stimulation of SpNs in a clinical setting.
[0223] The transient changes observed during SpN stimulation were shown to be amplitude and frequency dependent. During 1 min of stimulation with different current amplitudes, the strongest decrease in mSpA BF was observed at the highest current amplitude tested, which also corresponded to the peak of eCAP recorded. This was true when stimulating the entire SpN plexus (with a periarterial cuff) or when stimulating only a few fascicles placed in a smaller cuff. The difference in the total charge density required to obtain maximum eCAP from the SpN plexus and from the SpN fascicles could be explained by the partial coverage of the plexus by using a 2.5 mm cuff. In fact, in most pigs, this cuff only provided a circumferential coverage of 270-300 degrees. When cuffing only a few fascicles of SpN dissected away from the artery, the coverage was almost total. Therefore, optimal circumferential coverage of the artery is required to limit the charge density required to obtain optimal recruitment of the SpN fascicles.
[0224] The strongest changes (in mSpA BF and sMABP) were observed at frequencies between 30 and 50 Hz. Although the total number of pulses delivered could be an important factor in determining the magnitude of this change, it is still true that the 30-50 Hz range induced the strongest changes when compared to changes caused by the same number of pulses delivered at different frequencies. This could be explained by previously reported data showing that the maximum release of NA from the cat spleen was observed at 30 Hz [17, 18]. The higher release of NA could explain the higher magnitude of changes observed in this stimulation range.
[0225] Study 3: Effects of electrical stimulation in an in vivo LPS animal model Materials and Methods animal A total of 18 pigs (initially >38) (age / weight) were used in this section of the study. None of these 18 pigs were excluded from the analysis.
[0226] General Design Three hours after the initial stimulation, which was performed as part of other study objectives, 18 animals received an intravenous injection of 2.5 μg / kg of endotoxin (lipopolysaccharide purified from cell membranes of Escherichia coli O111:B4; Sigma-Aldrich), administered over a 5-minute period. This dose was selected through a thorough review of the available literature and personal experience. This dose was chosen to induce a septic shock type of model. Animals that received the SpN stimulation 3 hours prior to LPS injection were divided into two groups. SpNS received no further stimulation, whereas SpN2S received a second SpN stimulation during the LPS injection.
[0227] Stimulation parameters were square, biphasic, charge-balanced symmetric pulses at 10 Hz with a pulse duration of 400 μs and 30 to 90 μC / cm 2 / phase with a current amplitude corresponding to the charge density per phase and a duration of 1 min. Stimuli were applied once and then repeated a second time 3 h later when LPS was injected in vivo.
[0228] Peripheral venous blood was collected immediately prior to LPS injection (baseline) and then every 30 min up to 2 h after injection. At the end of this period, pigs were either euthanized or used for further terminal electrophysiological testing. Cytokine analysis (TNFα and IL-6) as well as routine hematology and biochemistry analyses were performed at all these time points. Serum was diluted 1:10 for cytokine analysis.
[0229] In animals in which LPS infusion caused clinical changes in systemic blood pressure and / or cardiac function, standard clinical treatments such as vasopressin (2.5 IU intravenous bolus and repeated as necessary) and antiarrhythmic drugs (lidocaine; 2 mg / kg intravenous and / or atropine; 40 μg / kg intravenous) were given at the discretion of the anesthesiologist. Animals were euthanized if mean systemic arterial pressure could not be maintained >40 mmHg or if the animal completed the pre-determined endpoint.
[0230] statistical analysis All analyses were performed with commercially available statistical software (JMP Pro 13.0.0). Continuous variables were visually inspected for inclusion and outliers. When outliers were identified, statistical tests were performed including and excluding these animals as described in the Results section.
[0231] Changes in cytokine and leukocyte levels were calculated as a percentage of the baseline sample taken immediately before LPS injection. Cytokine and leukocyte levels were subsequently analyzed using a mixed model with stimulation group, time, and the product of stimulation group and time as fixed effects and animal as a random effect. Paired Student's t-tests were used for post-hoc analysis. Differences in survival time between stimulation groups were analyzed using the log-rank test and plots in Kaplan-Meier plots. Cytokine levels, leukocytes, and electrolytes were compared between the different treatment groups at 30 min after LPS injection using two-way ANOVA with post-hoc all-pairs Student's t-test analysis. This test was also used to compare the maximum decrease in mean arterial blood pressure between groups. Statistical significance was defined as P<0.05.
[0232] result survival Administration of high doses of LPS caused rapid changes in systemic arterial blood pressure within 5 to 10 minutes after LPS administration. In sham (unstimulated) animals, these changes were stronger and more rapid. Many animals required therapeutic intervention (e.g., vasopressin infusion) to maintain safe levels of blood pressure (mean ABP > 40 mmHg). However, in most animals, therapeutic intervention was not sufficient to restore safe levels of ABP, and the animals had to be euthanized. In addition, several animals showed tachyarrhythmias and severe tachycardia. Stimulated animals (especially those that received two splenic nerve stimulations) showed lower magnitude changes and more stable cardiovascular responses. Events recorded after LPS administration in stimulated and sham animals are summarized in Table 2.
[0233] Table 2 describes the cardiovascular changes after LPS administration. The table shows the changes in mean arterial blood pressure (MABP) observed in the animals after LPS administration and the treatments administered to the individual pigs. Time represents the time after LPS injection. MASS = external chest (cardiac) massage, VAS = vasopressin administration (2.5 μg / kg intravenous), ATR = atropine administration, LID = lidocaine administration, Euth time = time (min) from LPS administration to euthanasia, the predefined endpoint was 120 min.
[0234] [Table 6]
[0235] Survival rates 2 hours after injection are shown in Figures 10A and 11A. There was a statistically significant difference in survival rates between SpN-T vs. Sham (P = 0.0194). In summary, LPS injection caused severe cardiovascular side effects within 10-20 minutes in 5 / 6 Sham animals, requiring euthanasia before reaching the predefined endpoint (MAP < 40 mmHg despite treatment). On the other hand, in 5 / 6 SpN-T stimulated animals and 4 / 6 SpN-P stimulated animals, life-threatening parameters including mean arterial blood pressure remained stable during the experimental period. In these groups, MAP at 2 hours after injection was 95.3 ± 13.5, 85.9 ± 7.5, and 86.8 ± 9.7% of baseline values, respectively. Similarly, there was a statistically significant difference in the maximum decrease in MAP between SpN-T vs. Sham (P = 0.0296, Figures 10B and 11B). The mean MAP at the time of euthanasia was 87.1 ± 23.5% of baseline in the SpN-T group (mean survival time after injection 1.8 ± 0.5 h), 62.7 ± 33.0% of baseline in the SpN-P group (mean survival time after injection 1.4 ± 0.8 h), and 48.6 ± 37.9% of baseline in the Sham group (mean survival time after injection 0.9 ± 0.7 h).
[0236] Cytokine quantification: For all groups, peak responses were observed at 1 hour post-infusion, resulting in a significant increase in TNFα levels in all post-infusion samples with LPS infusion compared to baseline (P<0.001, Figures 10C-10D and Figures 11C-11D). IL-6 was significantly higher at 2 hours post-infusion compared to baseline (P<0.0001) across all groups.
[0237] When comparing cytokine levels 0.5 h after injection, no significant differences were found in IL-6 levels as well as TNFα levels between sham and stimulated groups (Figs. 10D, 11C, and 11D).
[0238] Consideration In vivo administration of LPS, which mimics an inflammatory response, provided a good model to test the efficacy of SpN. Administration of LPS (2.5 μg / kg body weight) to 45-50 kg pigs resulted in increased expression of cytokines (TNFα and IL-6) in the blood of all animals tested. In particular, TNFα reached a peak value of about 12 ng / ml 1 hour after injection, whereas IL-6 was around 15 ng / ml 2 hours after LPS. LPS also caused significant changes in peripheral blood composition, decreasing circulating lymphocytes and neutrophils (results not shown). Leukocytes indeed leave the circulation during the systemic infection mimicked by LPS, presumably to infiltrate tissues and organs. Significant increases in blood urea, creatinine, and total bilirubin were also observed after LPS, in addition to increases in CK and ALP over time (results not shown). All these changes indicate that the model is valid and reproducible between animals.
[0239] Surprisingly, the sham animals showed a very rapid and strong decrease in systemic MABP approximately 10-15 min after LPS administration. The decrease in systemic MABP quickly reached life-threatening levels, necessitating vasopressin administration. However, this was not sufficient to stably restore normal sMABP in most shams. Even with further infusions of vasopressin, 4 / 6 of the sham controls had to be euthanized 30 min after LPS injection because their sMABP could not be maintained above 40 mmHg. One of the shams was instead euthanized 110 min after LPS injection for the same reason. In some cases, arrhythmias were also observed.
[0240] In contrast, most animals stimulated (either at -3 h or at -3 and 0 h to LPS) did not show such strong changes in sMABP. Most of them did not require any pharmacological intervention (i.e. vasopressin). However, this pro-survival effect of SpN stimulation could not be explained by a decrease in the concentration of LPS-induced cytokines. In fact, TNFα and IL-6 measured 30 min after LPS injection in stimulated animals were not decreased when compared to sham animals. Therefore, even if this model provided evidence that SpN stimulation can modulate the response to inflammatory stimuli, this could not be simply explained by a decrease in the inflammatory response. However, it must be considered that further comparisons of cytokine levels (at 1, 1.5, and 2 h after LPS) between stimulated and sham animals could not be performed because most shams had to be euthanized within 30 min after LPS administration. Therefore, differences in cytokine levels could have been observed at later time points when TNFα and IL-6 reach their peak values.
[0241] Therefore, the data suggest that the pro-survival effect was due to modulation of some other mechanism.
[0242] overview In summary, the inventors found that neural stimulation of the nerves innervating the spleen, particularly the splenic artery nerve, showed survival-promoting effects in an in vivo LPS animal model. The inventors also found that electrical stimulation of the splenic artery nerve stabilized the dramatic fall in blood pressure in LPS-treated animals and reduced the maximum fall in blood pressure. Thus, stimulation of the neural activity of the splenic nerve can be useful for treating acute diseases and cardiovascular dysfunction, such as life-threatening conditions with physiological changes associated with shock (e.g., trauma, hemorrhage, and septic shock).
[0243] Study 4: Effects of electrical stimulation in an in vivo LPS sublethal animal model Materials and Methods animal A total of eight female large white pigs (weight 60-70 Kg) were used in this section of the study.
[0244] general design On the day of the study, one animal was sedated with ketamine / midazolam. Intravenous anesthesia was induced by administration of propofol (2mg / Kg) via a catheter placed in the auricular (ear) vein. An endotracheal tube was then inserted into the trachea with the primary goal of establishing and maintaining a patent airway, and also to maintain general anesthesia using sevoflurane contained in an oxygen / air mixture. After induction of general anesthesia, the animal was instrumented with invasive femoral artery and jugular venous catheters to monitor blood pressure in addition to providing fluids / medications. The animal was then positioned in a right lateral decubitus position. Depth of anesthesia was monitored using eyelid reflex, corneal reflex, midventral eye position, and jaw tone. Nystagmus was also monitored in addition to lacrimation as possible signs of a light level of anesthesia. Electrocardiogram (ECG), heart rate (HR), respiratory rate (RR), systemic arterial blood pressure (ABP), central venous pressure (CVP), pulse oximetry, capnography, spirometry, and temperature were monitored throughout the procedure. Animals were instrumented with a catheter as well as a continuous cardiac output measurement system (PICCO) in the pulmonary artery for cardiac output and pulmonary wedge pressure measurements. All physiological parameters as well as the percentage of inhaled sevoflurane were recorded continuously via a Powerlab acquisition system and Labchart software, as well as on a record sheet (every 5 min). Animals were mechanically ventilated with positive pressure for the duration of the procedure. The splenic artery and nerve were subsequently accessed via a lateral laparotomy. A cuff was placed at the level of the proximal splenic artery to stimulate the splenic nerve. Stimulation was applied for 2 min at 10 Hz with a range of amplitudes. Sham animals did not receive any stimulation. Fifteen minutes after the end of the stimulus, animals received an intravenous injection of 2.5 μg / kg endotoxin (lipopolysaccharide purified from the cell membranes of E. coli O111:B4; Sigma-Aldrich), administered over a 5-minute period. This dose was chosen to elicit significant cardiovascular effects without shock in the 4-6 hour window following LPS administration. Approximately 30 minutes after LPS injection, a second stimulus (or sham stimulus) was delivered.
[0245] Stimulation parameters were square, biphasic, charge-balanced symmetric pulses at 10 Hz with a pulse duration of 400 μs (per phase) and 40 to 90 μC / cm 2 The current amplitudes correspond to a charge density per phase of 1 min.
[0246] Peripheral venous blood was collected immediately prior to LPS injection (baseline) and then every 30 min up to 4 h after injection. At the end of this time window, pigs were euthanized. Cytokine analyses (TNFα and IL-6) as well as routine hematology and biochemistry analyses (including lipase and amylase) were performed at all these time points.
[0247] Cardiac output was measured continuously with a PICCO system and using a pulmonary artery catheter before and 30 min after LPS infusion to obtain pulmonary capillary wedge pressure (PCWP).
[0248] result Stimulation effects on cardiovascular parameters Administration of LPS induced significant changes in ABP, CVP, HR, and ET CO2. Interestingly, animals receiving electrical stimulation of the splenic nerve showed lower magnitude changes in ABP, CVP, and HR (Figures 13A and B).
[0249] Injection of LPS also caused a significant increase in pulmonary vascular resistance (PVR) 30 min after LPS injection. However, when animals were stimulated, a stable and decreasing PVR was observed (Figure 14A). In parallel, stimulation caused a slightly stronger increase in systemic vascular resistance (SVR) compared to sham animals (Figure 14B) and a stronger increase in PCWP (Figure 14C).
[0250] Finally, LPS injection caused a marked upregulation of circulating levels of lipase, although this increase was much smaller in splenic nerve stimulated animals (FIG. 15).
[0251] Consideration Stimulation of the splenic nerve in pigs subjected to endotoxemia (sublethal systemic LPS administration) caused a significant stabilization of the cardiovascular changes induced by LPS. In particular, the increased SVR and decreased PVR may explain the positive output in the septic shock model described previously. This parallels the smaller magnitude changes in CVP, ABP, and HR after LPS administration, in addition to the suppression in LPS-induced lipase increases, indicating a lower level of organ damage and a stronger protection compared to sham animals.
[0252] Human Data Study 5: Electrophysiological characterization of the human splenic nerve Materials and Methods Human SpN specimens One freshly harvested tissue from a donor patient containing the splenic neurovascular bundle NVB was stored in a solution suitable for organ transplantation on ice for transport. Upon arrival, the specimen was placed in well-chilled Krebs solution under a dissecting microscope and a minimum of one individual SpN fascicle per sample was carefully isolated from the SpA, followed by attachment of two bipolar circumferential cuff electrodes (0.65 mm diameter, 5.5 mm length; CorTec Corporation) placed approximately 10 mm apart to induce and record CAP. Fascicle electrode coverage was estimated to be 100% in all grafts.
[0253] record Nerve activity was continuously monitored using an oscilloscope and digitally recorded via a 1401 digital acquisition system and Spike2 software (Cambridge Electronic Design Ltd) with a sampling rate set at 20 kHz. Evoked CAPs were averaged (8 pulses) and the peak-to-peak amplitude of the averaged response was quantified. The conduction velocity of the eCAP component was calculated from the measured distance between the stimulation and recording sites and the latency of the eCAP signal (measured from the peak of the stimulation artifact to the peak of the eCAP).
[0254] result Compared to the porcine samples, human SpA presented a more complex course than previously described (Michels 1942). Furthermore, the splenic NVB was embedded in extensive amounts of connective tissue and fat (Fig. 16A), making recordings from the entire circumference of the construct difficult. However, using a dissecting microscope, some nerve bundles could be seen, which was later confirmed as such by histological sections of the specimen (Fig. 16B). After attaching stimulation and recording cuff electrodes to some of these fiber bundles (Fig. 16A, top and bottom images), stimulation produced clear eCAPs (Fig. 16D, top output trace). To verify the reliability of the recordings at the end of the experiment, fiber bundles were crushed between the stimulation and recording electrodes, and re-recording attempts were made (Fig. 16D, bottom output trace). When stimulation was applied at specific pulse durations (e.g., PW 100, 200, 400, 800, and 1000 μs) and increasing amplitudes, typical recruitment curves were obtained (Fig. 16E).
[0255] The calculated conduction velocities showed typical values for unmyelinated fibers, with the range and mean of conduction velocity being 0.49 m / s compared to pig (0.7 m / s) and rat (0.72 m / s) SpNs (Figure 16F). In addition, eCAP recordings of human SpNs showed a typical strength-duration relationship between current amplitude and pulse duration for nerve recruitment (Figure 16G). Linear regression of calculated charge density values for eCAP threshold recordings yielded a value of 13.44 μC / cm 2 Requires minimum PW(100μs) and 14.7μC / cm 2 The longest PW (2000 μs) required a slope significantly different from zero (P = 0.0084). Importantly, the slope of the charge density for human SpN fascicles was found to be similar to that for porcine fascicles (FIG. 16H). In addition, the charge density requirement for neural activation of dissected human fascicles was approximately 1.5-2 times higher than the charge density required for activation of porcine SpN fascicles at any PW (FIG. 16H).
[0256] Consideration Human SpNs have similar anatomical, morphological, and electrophysiological properties to other mammals (pig and rodent). Human SpNs are composed of unmyelinated axons as confirmed by conduction velocity. Therefore, it is understood that stimulation parameters (frequency and waveform) optimized in pigs are assumed to be appropriate for the human splenic nerve. However, charge requirements need to be calculated from the entire NVB.
[0257] Study 6: Histomorphometric characterization of human splenic structures The purpose of this study was to increase understanding of human splenic structure and estimate the approximate dimensions of the splenic neurovascular bundle (NVB) using histology (see Table 2). The study was performed on splenic tissue received from organ transplant patients. Histomorphometric estimates were calculated for luminal diameter, arterial wall, fascicle diameter (mean Feret's diameter), and approximate distance of each fascicle from the adventitia (outer splenic arterial wall).
[0258] Materials and Methods Five human splenic NVBs were provided by organ transplant patients at Addenbrooke's Hospital, Cambridge, UK. Tissues were immersed in 10% neutral buffered formalin (NBF) as soon as possible after excision. Tissues were photographed with a ruler presented for gross measurements (see Figure 17A). Samples were divided into 0.5-1.5 cm contiguous blocks for histology (see Figure 17B). Periarterial tissue was retained for inclusion in the blocks. Sections were embedded and sectioned so that the same face of each block (i.e., proximal or distal to the spleen) was sampled each time. Sections were usually 4-5 μm thick and stained with hematoxylin and eosin (H&E) (see Figure 17C). Finally, tissue quality was checked by a pathologist and glass slides were scanned at x20. Note that 10% tissue shrinkage was compensated for as per literature. However, arterial diameters represent zero pressure. All samples received from organ transplant patients showed a high amount of adipose tissue, and the fiber bundles were found to be embedded within a thick layer of adipose tissue.
[0259] [Table 7]
[0260] For quantification purposes, the splenic tissue was divided into three sections: proximal, mid, and distal. Each of these sections consisted of several sections. The proximal end was closer to the abdominal cavity, as indicated by the sutures in Figure 17A, and the distal was closer to the spleen. Neither of these would be suitable intervention sites for neural interface placement. The mid section with the loop would be suitable as an intervention site.
[0261] In summary, the diameter of the fascicles ranges from 20 to 400 um, as shown in Figure 18. Regarding the extent of the fascicles, about half of the nerve fibers were found in the 0-1 mm area, 30% in the 1-2 mm area, 15% in the 2-3 mm area, and the remainder in the area of about 3-4 mm.
[0262] Study 7: Transformational charge requirements from porcine to human splenic neurovascular bundles Materials and Methods A 3D finite element method model computer simulation was created using histological data from porcine and human spleen histology. It basically consists of the splenic artery (lumen + arterial wall) and extravascular tissue. The "extravascular tissue" consists of "adipose tissue" and "connective tissue" with nerves embedded in the tissue. For the pig, a model with a split in the Cortec cuff (representing the in vivo cuff) was used. For the human model, a cuff with three arms structure was used. The diameter of the cuff used was 9mm.
[0263] Considering the differences between porcine and human histology, a) porcine fascicles are evenly distributed and closely spaced around the arteries, whereas human fascicles appear to be more dispersed; and b) porcine histology shows only small amounts of adipose tissue outside the blood vessels, contrary to the substantial amounts in humans.
[0264] To translate the stimulation parameter estimates from pig to human, modelling was performed in two stages: Stage (a): A 3D finite element model (FEM) was developed in the Sim4Life simulation tool. Using Sim4Life, a representative nerve and artery model (based on histology and image quantification), the cuff and electrodes (CAD-defined specifications), and the 3D voltage field were constructed. Stage (b): The FEM solution was solved in the same tool. Using Sim4Life, the voltage was interpolated along the axon using Sundt's nerve model
[19] and the axonal simulation estimated the strength-duration and population recruitment curves.
[0265] result Figure 19A represents in vivo acute data from the porcine splenic neurovascular bundle from five animals. The range from the five animals for charge requirements was approximately 20 to 160 μC / cm at <50 mA, 400 us and 10 Hz. 2 The charge requirement for the third animal, shown in grey, is estimated to be approximately 100 μC / cm at 30 mA, 400 μs and 10 Hz. 2 which correlates well with the in silico simulated data (see FIG. 20A). Using the in silico vs. in vivo correlation as a validation of the computational model in pigs, the charge requirements were translated to the human splenic neurovascular bundle using tissue sections for the two pulse widths. The data are presented in FIG. 20C-D and Table 3.
[0266] [Table 8]
[0267] The charge requirement in a human acute model for 100% mobilization is likely to be about 80 to 1300 μC / cm 2 (400uS pulse width, 12mm 2 surface area) and 70 to 1100 μC / cm 2 (using a 1ms pulse width) is estimated to vary from 350μC / cm 2Lower, approximately 70% mobilization is indicated. An additional 30% mobilization requires an exponential increase in charge requirements beyond what can be accommodated by the implantable device. For example, 100% mobilization may require 70-1300 μC / cm 2 , 80% mobilization is 70-450 μC / cm 2 , 50% mobilization is 70-250 μC / cm 2 , and 30% mobilization is 70-170 μC / cm 2 It can be seen that the
[0268] Consideration Nerve fibers in humans are more dispersed compared to pigs. The extent of the diffuse fiber bundles around the splenic artery as shown by histological profiling can range from about 1 to 3 mm. The histomorphometric data was further used to optimize stimulation parameters using computational modeling tools and to translate the charge requirements from pigs to humans. Using the Sundt C-fiber model, the charge requirements for humans were estimated to be about 70 to 1000 μC / cm for 100 percent recruitment. 2 It was shown to be in the range of
[0269] References [1] JMHuston et al., J Exp Med 203, 1623 [2] R. Medzhitov, Nature 454, 428-435 (July 24, 2008) [3] Greenway et al., J. Physiol. (1968), 194, 421-433 [4] G. Vida, G. Pena, EA Deitch, L. Ulloa J Immunol 186, 4340 [5] U.S. Patent Publication No. 2006 / 0287678 [6] U.S. Patent Publication No. 2005 / 0075702 [7] U.S. Patent Publication No. 20050075701 [8] F. Tischendorf F, Biol Lat 9:307‐342, 1956 [9] M. Fillenz, Proc R Soc Lond B Biol Sci 174:459-468, 1970
[10] I.G. Zelenova, Arkh Anat Gistol Embriol 60:88-90, 1971
[11] F.D. Reilly, Experientia 41:187-192, 1985
[12] D.L. Felten et al., J Neurosci Res 18:28-36, 118-121, 1987
[13] D.G. Onkar, J Morphol Sci 30:p.16-20, 2013
[14] D. Bakovic et al., Clin Exp Pharmacol Physiol 32:944-951, 2005
[15] A. Lodin-Sundstrom, E. Schagatay, Aviat Space Environ Med 81:545-549, 2010
[16] Schafer, E.A. and Moore, B., J Physiol., 1896
[17] G.L. Brown, J.S. Gillespie JS, J Physiol, 138:81-102, 1957
[18] A.G. Garcia et al., J Physiol, 261:301-317, 1976
[19] Sundt D et al., Journal of neurophysiology.114:3140-53, 2015
Claims
1. 1. A system for stimulating neural activity of a nerve innervating the spleen to treat an acute condition, said nerve being connected to a neurovascular bundle, preferably the splenic artery nerve, The system includes at least one electrode for signal transducing contact with the nerve; at least one controller electrically connected to the at least one electrode and configured to control operation of the at least one electrode to apply an electrical signal to the nerve; the electrical signal results in an improvement in a physiological parameter indicative of treatment of the acute condition; The improvements in the physiological parameters include: restoration of body temperature to between 36° C. and 38° C.; restoration of heart rate to between 60 and 100 bpm; restoration of systemic arterial pressure to between 90 / 60 mmHg and 150 / 90 mmHg; restoration of systemic venous pressure to about 5 mmHg in the right atrium and about 8 mmHg in the left atrium; restoration of pulmonary blood pressure to about 15 mmHg; restoration of central venous pressure to a range of about 3 to 8 mmHg; restoration of respiratory rate to 8 to 14 breaths per minute; increase in oxygen saturation to 94% or greater; the system exhibits any of the following symptoms: increased arterial blood oxygen pressure, restoration of arterial blood carbon dioxide pressure to 4.4-6.1 kPa, relief of pain, restoration of urine output to 0.5 ml / kg / hr or more, increased level of consciousness, reduction in lactate levels, changes in blood glucose levels, changes in blood base deficit levels and changes in arterial pH levels, increased systemic vascular resistance and pulmonary capillary wedge pressure while pulmonary vascular resistance is restored to lower levels, suppression of elevated levels of lipase, and suppression of elevated levels of amylase.
2. The system of claim 1 , wherein the acute condition is life threatening, such as trauma, hemorrhage, or septic shock.
3. The system of claim 1 or 2, further comprising a neural interface, said neural interface comprising said at least one electrode.
4. The system of claim 3 , wherein the neural interface is adapted for placement around at least one splenic nerve.
5. 5. The system of claim 3, wherein the neural interface is adapted for placement around the splenic artery.
6. The system of claim 3 , wherein the neural interface is adapted for placement over at least one splenic artery nerve.
7. 7. The system of claim 3, wherein the neural interface is adapted for placement on the splenic artery.
8. The system of claim 3 , wherein the neural interface is adapted for placement within at least one splenic nerve.
9. The system of claim 3 , wherein the neural interface is adapted for placement in the splenic artery.
10. 10. The system of claim 3, wherein the deployment site is separated from the surface of the pancreas.
11. The system of claim 10 , wherein the deployment site is in a splenic artery loop.
12. 12. The system of claim 1, wherein the at least one electrode comprises a first electrode and a second electrode.
13. 13. The system of claim 12, wherein the first electrode is an anode and the second electrode is a cathode.
14. 14. The system of claim 12 or 13, wherein the second electrode is configured to be in signal transmitting contact with the nerve and the first electrode is configured not to be in signal transmitting contact with the nerve, optionally the first electrode is grounded, and optionally the first and second electrodes form a monopolar configuration.
15. 15. The system of claim 12 or 14, wherein the at least one electrode further comprises a third electrode, and the second electrode is positioned between the first electrode and the third electrode in the longitudinal axis direction of the nerve.
16. The system of claim 15 , wherein the third electrode is an anode.
17. 17. The system of any of claims 12-16, wherein the width of the first electrode and the third electrode is between 0.5 and 4 mm, optionally between 0.5 and 2 mm, optionally between 0.5 and 1.5 mm, further optionally between 0.7 and 1 mm, optionally between 1 and 4 mm, optionally between 1 and 3 mm, optionally between 2 and 4 mm, optionally between 2 and 3 mm.
18. 18. A system according to any of claims 12 to 17, wherein the distance between the first and second electrodes and / or the distance between the second and third electrodes is between 5mm and 7mm, optionally between 5.5mm and 6.5mm, and further optionally between 6.2mm and 6.4mm, when dependent on claim 33, 34 or 35.
19. 19. The system of claim 1, further comprising a signal generating unit configured to deliver the electrical signal to the at least one electrode in response to a control operation from the control unit.
20. 20. The system of claim 19, wherein the signal generator comprises at least one current or voltage source.
21. 21. A system according to any preceding claim, wherein the electrical signal has a frequency of less than 300 Hz and is applied periodically.
22. 22. A system according to any preceding claim, wherein the electrical signal has a frequency of less than 50 Hz and is applied continuously.
23. The charge density per phase applied to the nerve by the electrical signal is cm per phase 2 Between 5 μC and 1100 μC per phase, and optionally between 100 μC and 1100 μC per phase 2 5 μC to 450 μC per phase, optionally cm per phase 2 5 μC to 150 μC per phase, optionally cm per phase 2 50 μC to 450 μC per phase, and optionally cm 2 23. The system of claim 1, wherein the temperature is between 50 μC and 160 μC per second.
24. 24. The system of any one of claims 1 to 23, wherein the at least one control unit comprises a processor and a non-transitory computer readable storage medium having an executable computer program comprising code portions that, when loaded and executed by the processor, cause the processor to at least control operation of the at least one electrode.
25. 1. A method for reversibly stimulating neural activity in a nerve innervating the spleen, said nerve being connected to a neurovascular bundle, preferably the splenic artery nerve, Providing the system of any one of claims 1 to 24; placing at least one electrode in signal transmitting contact with the nerve; applying an electrical signal to the at least one splenic nerve to stimulate neural activity by controlling operation of the at least one electrode with at least one controller; A method for providing the above.
26. 26. The method of claim 25, wherein the method is for treating an acute condition such as trauma, hemorrhage, or septic shock.
27. 1. A method for treating an acute condition such as trauma, hemorrhage, or septic shock, comprising applying an electrical signal to stimulate neural activity of a nerve innervating the spleen, the nerve being associated with a neurovascular bundle, preferably the splenic artery nerve, the electrical signal improving physiological parameters indicative of treatment of the acute condition, the improvements in physiological parameters being restoration of body temperature to between 36° C. and 38° C.; restoration of heart rate to between 60 and 100 bpm; restoration of systemic arterial pressure to between 90 / 60 mmHg and 150 / 90 mmHg; restoration of systemic venous pressure to about 5 mmHg in the right atrium and about 8 mmHg in the left atrium; restoration of central venous pressure to a range of about 3 to 8 mmHg; restoration of central venous pressure to a range of about 15 mmHg; the restoration of pulmonary blood pressure to 95-120 Hg, the restoration of respiratory rate to 8-14 breaths per minute, an increase in oxygen saturation to 94% or greater, an increase in arterial blood oxygen pressure to 12-15 kPa, the restoration of arterial blood carbon dioxide pressure to 4.4-6.1 kPa, relief of pain, restoration of urine output to 0.5 ml / kg / hr or greater, an increase in level of consciousness, a decrease in lactate levels, a change in blood glucose levels, a change in blood base deficit levels and a change in arterial pH levels, an increase in systemic vascular resistance and pulmonary capillary wedge pressure while pulmonary vascular resistance is restored to lower levels, an inhibition of elevated levels of lipase, and an inhibition of elevated levels of amylase.
28. 28. The method of claim 27, wherein the method is performed by the system of any of claims 1 to 24.
29. 1. A computer-implemented method for reversibly stimulating neural activity in a nerve innervating the spleen, said nerve being connected to a neurovascular bundle, preferably the splenic artery nerve; 25. A method comprising controlling operation of at least one electrode of the system of any one of claims 1 to 24 to apply a signal to the nerve to stimulate neural activity.
30. 30. The method of claim 29, wherein the method is for treating an acute condition such as trauma or septic shock.
31. 31. A neurostimulatory electrical signal for use in a method for treating an acute condition such as trauma, hemorrhage, or septic shock, the electrical signal being the electrical signal of any one of claims 1 to 30.
32. 25. A modified nerve in signal-transmitting contact with the neural interface of the system of any one of claims 1 to 24, the nerve innervating the spleen and associated with a neurovascular bundle, preferably the splenic artery nerve, the at least one electrode in signal-transmitting contact with the nerve, such that the nerve can be distinguished from the nerve in its native state, the modified nerve being present in a subject suffering from trauma, hemorrhage, or an acute disease such as septic shock.
33. 32. The modified nerve of claim 31 , wherein the modified nerve is a splenic artery nerve.
34. 33. The modified nerve of claim 32, wherein the at least one electrode contacts the nerve at a location where the splenic artery does not directly contact the pancreas.
35. 35. The modified nerve of claim 34, wherein the site is a splenic artery loop.
36. A modified nerve obtainable by stimulating the neural activity of a nerve innervating the spleen, 31. A modified nerve by the method according to any one of claims 25 to 30, wherein the nerve is connected to the neurovascular bundle, preferably to the splenic nerve.
